CV - Kemerburgaz Üniversitesi
Transkript
CV - Kemerburgaz Üniversitesi
ÖZGEÇMİŞ VE ESERLER LİSTESİ ÖZGEÇMİŞ Adı Soyadı: Mehmet Murat İnal Doğum Tarihi: 18 Ocak 1970 Öğrenim Durumu: Derece Bölüm / Program Üniversite Yıl Y.Lisans Tıp Fakültesi Hacettepe Üniversitesi 1996 Kadın Hastalıkları ve SSK Ege Doğumevi ve Kadın 2001 Doğum Hastalıkları Eğitim ve Araştırma (İngilizce) Tıpta Uzmanlık Hastanesi Doçentlik Kadın Hastalıkları ve Gazi Üniversitesi (Sınav Yeri) 2007 Doğum Yan Dal Uzmanlık Jinekolojik Onkoloji 2011 Cerrahisi Doktora Tezi/S.Yeterlik Çalışması/Tıpta Uzmanlık Tezi Başlığı (özeti ekte) ve Danışman (lar)ı : “Endometrial Ablasyon Sonrası Endometriumun Ofis Histeroskopi ile Alınan Biyopsilerle Değerlendirilmesi ve Endometrial Ablasyonun Tedavi Edici Etkilerinin İncelenmesi” (2001). Tez Danışmanı: Dr Ahmet Seçkin Önoğlu 1 Görevler: Görev Ünvanı Görev Yeri Yıl Asistan Doktor SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi 1997-2001 Uzman Doktor Sağlık Bakanlığı Ege Doğumevi ve Kadın Hastalıkları 2001-2008 Eğitim ve Araştırma Hastanesi Doçent Doktor Antalya Medical Park Hastane Kompleksi 2010-2014 Antalya Medical Park Hastane Kompleksi 2014 - (Bölüm Başkanı) Profesör Doktor İstanbul Kemerburgaz Üniversitesi Tıp Fakültesi Yönetilen Doktora Tezleri/Sanatta Yeterlilik/Tıpta Uzmanlık Tez Çalışmaları: 1. Yıldırım, Y., “Renal Transplant Hastalarında Ovaryan Fonksiyon ve Fertilite”, SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi, 2003. 2. Karacaer, M., “Nöral Tüp Defektlerinde Faktör V (1691GA) Leiden ve Protrombin 20210GA Genetik Polimorfizminin Araştırılması”, SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi, 2004. 3. Şentaş, A., “Endometriozis Patogenezinde Anjiogenik Faktörlerden “Transforming Growth Factor”ün Önemi”, SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi, 2004. 4. Karaltı, M.O., “Nöral Tüp Defektlerinde 5,10-Metilentetrahidrofolat redüktaz (MTHFR) Genetik Polimorfizminin Araştırılması”, SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi, 2004. 5. Naykı, C., “Erken Doğum Eylemi Tedavisinde Direkt Tokolitik Ajanlar ile Hidrasyon-Sedasyon-Yatak İstirahati ve Etkene Yönelik Tedavinin Karşılaştırılması”, SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi, 2004. 6. Altındağ, M., “Epitelyal Over Tümörlerinde Thomsen-FriedenReich Antijenin İmmünohistokimyasal Yöntemle Değerlendirilmesi”, SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi, 2005. 2 7. Uğurlu, T., “Fetal Kromozomal Anomalilerin QF-PCR (Kantitatif Floresan Polimeraz Zincir Reaksiyonu) ile Tespiti ve Etkinliğin Amniosit Kültürleri ile Karşılaştırılması”, SB Ege Doğumevi ve Kadın Hastalıkları Eğitim ve Araştırma Hastanesi, 2007. Projelerde Yaptığı Görevler: 1. “Implanon Uygulama ve Kabul Edilebilirlik Çok Merkezli Pilot Çalışması” Sağlık Bakanlığı AÇSAP Derialtı Kontraseptif İmplant Projesi, Uygulayıcı, 2002. 2. “Medikal Abortus Çok Merkezli Çalışması” Dünya Sağlık Örgütü, “Gynuity Health Projects”, Uygulayıcı, 2007. İdari Görevler: Yönetim Kurulu Üyeliği, Türk Jinekoloji ve Obstetrik Derneği, İzmir Şubesi, 2002-2004 Bilimsel Kuruluşlara Üyelikler: 1. Türk Jinekoloji ve Obstetrik Derneği 2. Türk Jinekolojik Onkoloji Derneği 3. European Society of Contraception (ESC) 4. European Society of Gynecological Oncology (ESGO) 5. International Gynecologic Cancer Society (IGCS) ESERLER A. Uluslararası hakemli dergilerde yayımlanan makaleler: A1. Sadik, S., Onoglu, AS., M.M. Inal, Guler, A., Arici, A., Ispahi, C., “Experience in Office Mini-hysteroscopy”, Gynecol Endoscopy, 11 (5): 251-256 (2002). A2. Taskin, O., Onoglu, A., M. Inal, Turan, E., Sadik, S., Vardar, E., Postaci, H., Wheeler, JM., “Long-term Histopathologic and Morphologic Changes after Thermal Endometrial Ablation”, J Am Assoc Gynecol Laparosc, 9 (2): 186-190 (2002). A3. Taner, C., M. Inal, Basogul, O., Onoglu, A., Karanfil, C., Tinar, S., Ispahi, C., “Comparison of the Clinical Efficacy and Safety of Flutamide versus Flutamide plus an Oral Contraceptive in the Treatment of Hirsutism”, Gynecol Obstet Invest, 54 (2): 105108 (2002). 3 A4. Vardar, E., Maral, I., M. Inal, Ozguder, O., Tasli, F., Postaci, H., “Comparison of Gram Stain and Pap Smear Procedures in the Diagnosis of Bacterial Vaginosis”, Infect Dis Obstet Gynecol, 10 (4): 203-207 (2002). A5. M.M. Inal, Ertopcu, K., Arici, A., Ozelmas, I., “The Effect of Oral versus Vaginal Misoprostol on Cervical Dilatation in First-trimester Abortion: A Double-blind, Randomized Study”, Eur J Contracept Reprod Health Care, 8 (4): 197-202 (2003). A6. Tinar, S., Sehirali, S., M.M. Inal, Yildirim, Y., Celik, E., Yigit, S., “Adenosarcoma of the Uterus: A Case Report”, MedGenMed (electronic resource): Medscape General Medicine, 6 (1): 51 (2004). A7. Yildirim, Y., M.M. Inal, Sanci, M., Sentas, A., Hanhan, M., “Uterine Sarcomas: A 10 Year Experience and A Review of the Literature”, Women’s Oncology Review, 4 (1): 7-12 (2004). A8. M.M. Inal, Hanhan, M., Pilanci, B., Tinar, S., “Fallopian Tube Malignancies: Experience of Social Security Agency Aegean Maternity Hospital”, Int J Gynecol Cancer, 14 (4): 595-599 (2004). A9. M.M. Inal, Hanhan, M., Demir, OF., Polat, M., Tinar, S., “Experience of SSK (Social Security Agency) Aegean Maternity Hospital on Choriocarcinomas”, Women’s Oncology Review, 4 (3): 169-174 (2004). A10. Sehirali, S., M.M. Inal, Ozsezgin, S., Sanci, M., Atli, O., Nayki, C., Yildirim, Y., Tinar S., “A Randomized Prospective Study of Comparison of Reservoir Ports versus Conventional Vascular Access in Advanced-Stage Ovarian Carcinoma Cases Treated with Chemotherapy”, Int J Gynecol Cancer, 15 (2): 228-232 (2005). A11. Ertopcu, K., M.M. Inal, Ozelmas, I., “Demographic Analysis of Post-Abortive and Interval-Administered Hormonal Contraceptive Methods”, Eur J Contracept Reprod Health Care, 10 (1): 1-5 (2005). A12. Yildirim, Y., Tinar, S., Yildirim, YK., M.M. Inal, “Comparison of Pituitary-Ovarian Function in Patients Who Have Undergone Successful Renal Transplantation and Healthy Women”, Fertil Steril, 83 (5): 1553-1556 (2005). A13. Yildirim, Y., M.M. Inal, Tinar, S., “Reproductive and Obstetric Characteristics of Adolescent Pregnancies in Turkish Women”, J Pediatr Adolesc Gynecol, 18 (4): 249-253 (2005). 4 A14. Yildirim, Y., M. Inal, Tinar S., “Necrotizing Fasciitis after Abdominal Hysterectomy: A Report on Five Cases”, Arch Gynecol Obstet, 273 (2): 126-128 (2005). A15. Sehirali, S., M.M. Inal, Yildirim, Y., Balim, Z., Kosova, B., Karamizrak, T., Sanci, M., Topcuoglu, N., Tinar, S., “Prothrombin G20210A Mutation in Cases with Recurrent Miscarriage: A Study of the Mediterranean Population”, Arch Gynecol Obstet, 273 (3): 170-173 (2005). A16. Yildirim, Y., M.M. Inal, Sanci, M., Yildirim, YK., Mit, T., Polat, M., Tinar, S., “Development of Uterine Sarcoma after Tamoxifen Treatment for Breast Cancer: Report of Four Cases”, Int J Gynecol Cancer, 15 (6): 1239-1242 (2005). A17. M.M. Inal, Ertopcu, K., Ozelmas, I., “The Evaluation of 318 Intrauterine Pregnancy Cases with An Intrauterine Device”, Eur J Contracept Reprod Health Care, 10 (4): 266271 (2005). A18. M.M. Inal, Incebiyik, A., Sanci, M., Yildirim, Y., Polat, M., Pilanci, B., Nayki, C., Camuzcuoglu, H., “Ovarian Cysts in Tamoxifen-Treated Women with Breast Cancer”, Eur J Obstet Gynecol Reprod Biol, 120 (1): 104-106 (2005). A19. M.M. Inal, Yildirim, Y., Taner, CE., “Comparison of the Clinical Efficacy of Flutamide and Spironolactone plus Diane 35 in the Treatment of Idiopathic Hirsutism: A Randomized Controlled Study”, Fertil Steril, 84 (6): 1693-1697 (2005). A20. Hanhan, M., M.M. Inal, Oztekin, D., Dicle, N., Ozsaran, Z., Tinar, S., “Prognosis of Early Invasive and Locally Advanced (stage I, II) Uterine Cervical Adenocarcinomas”, Cancer Therapy, vol 4: 263-270 (electronically published) (2006). A21. M. Inal, Yildirim, Y., Incebiyik, A., Sanci, M., Ispahi, C., “Diagnostic Accuracy of Sonohysterography in the Evaluation of Uterine Cavities in Tamoxifen Administered Asymptomatic Postmenopausal Breast Cancer Patients with Endometrial Thickness ≥5 mm”, Gynecol Surg, 3 (4): 271-274 (2006). A22. M.M. Inal, Yildirim, Y., Ertopcu, K., Ozelmas, I., “The Predictors of Retained Products of Conception Following First-trimester Pregnancy Termination with Manual Vacuum Aspiration”, Eur J Contracept Reprod Health Care, 11 (2): 98-103 (2006). A23. Onoglu, AS., Taskın, O., M. Inal, Sadik S., “Comparison of the Long Term Histopathologic and Morphologic Changes after Endometrial Roller-ball Ablation and Resection: A Prospective Randomized Trial”, The J Min Inv Gyn, 14 (1): 39-42 (2007). 5 A24. M.M. Inal, Kose, S., Yildirim, Y., Ozdemir, Y., Toz, E., Ertopcu, K., Ozelmas, I., Tinar, S., “The Relationship Between HPV Infection and Cervical Intraepithelial Neoplasia (CIN) in Turkish Women”, Int J Gynecol Cancer, 17 (6): 1266–1270 (2007). A25. M.M. Inal, Yildirim Y., Ertopcu K., Avci ME., Ozelmas I., Tinar S., “Effect of the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up)”, Eur J Contracept Reprod Health Care, 13 (3): 23842 (2008). A26. Yildirim Y., Gultekin E., Avci ME., M.M. Inal, Yunus S., Tinar S., “Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer”, Int J Gynecol Cancer, 18 (2): 223-7 (2008). A27. Onay H., Ugurlu T., Aykut A., Pehlivan S., M. Inal, Tinar S., Ozkinay C., Ozkinay F., “Rapid prenatal diagnosis of common aneuploidies in amniotic fluid using quantitative fluorescent polymerase chain reaction”, Gynecol Obstet Invest, 66 (2): 104-10 (2008). A28. Kose S., Ersan G., Sender SS., Devrim I., M.M. Inal., “A prevalence study of Chlamydia infections in Turkish population”, Braz J Infect Dis, 17 (1): 114-5 (2013). B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler : B1. C. Taner, Inal M., O. Basogul, A. Onoglu, C. Karanfil, S. Tinar, C. Ispahi, “Comparison of the Clinical Efficacy and Safety of Flutamide versus Flutamide plus An Oral Contraceptive in the Treatment of Hirsutism”, The Second World Congress on Controversies in Obstetrics Gynecology & Infertility, Paris, France, September 6-9, 2001. B2. K. Ertopcu, G. Undar, Z. Benli, H. Unluoglu, S. Coskun, Inal M., I. Ozelmas, “Demographic Analysis of Postabortive and Interval Hormonal Contraceptive Method Applicated Cases”. The 7th Congress of the European Society of Contraception, Genova, Italy, April 2002. B3. K. Ertopçu, G. Undar, Inal M., S. Tinar, I. Ozelmas, “Evaluation of 100 cases who have Pregnancies with IUDs and Want Their Pregnancies to Continue”, The 7th Congress of the European Society of Contraception, Genova, Italy, April 2002. B4. S. Sehirali, Z. Balim, Inal M.M., B. Kosova, T. Karamizrak, N. Topcuoglu, M. Sanci, S. Tinar, “The Evaluation of Factor V Leiden and Prothrombin 20210A in Preeclampsia 6 Cases”, 5th Congress of the European Society of Gynecology, Rhodes, Greece, October 9-11, 2003. B5. Z. Balim, S. Sehirali, Inal M.M., B. Kosova, O. Atli, N. Topcuoglu, T. Karamizrak, S. Tinar, “Evaluation of Factor V Leiden and Prothrombin 20210A Mutations in Cases with Diagnosis of Habitual Abortus”, 5th Congress of the European Society of Gynecology, Rhodes, Greece, October 9-11, 2003. B6. A. Incebiyik, Inal M.M., M. Sanci, H. Camuzcuoglu, B. Pilanci, “Comparison of Transvaginal Sonohysterography and Office Hysteroscopy in Evaluation of Uterine Cavities of Tamoxifen Administered Postmenopausal Cases with Breast Cancer”. 5th Congress of the European Society of Gynecology, Rhodes, Greece, October 9-11, 2003. B7. K. Ertopcu, Inal M.M., A. Donmez, I. Ozelmas, S. Tinar, “Interval versus Postabortive Counseling: Demographic Characteristics and Effect of Reproductive Desire on Method Selection (14332 cases)”, The 8th Congress of the European Society of Contraception, Edinburgh, Britain, June 2004. B8. Inal M.M., K. Ertopcu, M. Karacaer, M. Polat, S. Yetkin, I. Bicer, I. Ozelmas, S. Tinar, “Effect of Subdermal Contraceptive Implant (Implanon®) on Biochemical Serum Parameters”, The 8th Congress of the European Society of Contraception, Edinburgh, Britain, June 2004. B9. Y. Yakut, B. Dilbaz, H. Aktun, M. Sezgen, C. Simsek, Z. Vural, S. Yılmaz, Inal M., G. Atılgan, D. Aksit, A. Koseli, R. Kose – Ministry of Health, Implanon Study Group, “One Year Follow-up of Patients on Implanon® for Contraception: A Multicentric Prospective Study”, The 8th Congress of the European Society of Contraception, Edinburgh, Britain, June 2004. B10. K. Ertopcu, Inal M.M., A. Donmez, I. Ergin, S. Yetkin, S. Vardar, O. Bicer, I. Ozelmas, “Effect of Contraception on Depression: Comparison of Edinburgh and Beck Depression Scales”, The 8th Congress of the European Society of Contraception, Edinburgh, Britain, June 2004. B11. Inal M.M., K. Ertopcu, C. Nayki, U. Nayki, A. Donmez, S. Vardar, I. Ozelmas, S. Tinar, “Effect of Subdermal Contraceptive Implant (Implanon®) on Hormonal Parameters”, The 8th Congress of the European Society of Contraception, Edinburgh, Britain, June 2004. 7 B12. Inal M.M., A. Incebiyik, N. Dicle, Y. Yildirim, M. Polat, A. Uysal, M. Altındag, M. Sanci, “Steroid Hormone Receptor Evaluation in the Endometria of the Tamoxifen Administered Cases with Breast Cancer”, 11th World Congress of Gynecological Endocrinology, Florence, Italy, February 2005. B13. S. Ozsezgin-Ocek, S. Sehirali, Inal M.M., M. Sanci, C. Ispahi, “Epidural Ports in Relief of Gynecological Cancer Pain”, 11th World Congress on Pain, IASP, Sydney, Australia, August 2005. B14. Inal M.M., “Genetic Evaluation in Habitual Abortions”. Proceedings of the 8th International Conference on “Emerging Technologies in Drug and Gene-based Therapeutics”, p169, Crete, Greece, September 2005. B15. K. Ertopcu, Inal M.M., Z. Ozenc, A. Donmez, G. Yildirimkaya, I. Ozelmas, S. Tinar, “Contraception Again with IUD after IUD Dislocation and IUD+Pregnancy (Evaluation of 6412 cases)”, The 9th Congress of the European Society of Contraception, İstanbul, Turkey, May 2006. B16. K. Ertopcu, Inal M.M., N. Kokturk, I. Ozelmas, S. Tinar, “Continuity of Implanon Usage after Three Years of Use”, The 9th Congress of the European Society of Contraception, İstanbul, Turkey, May 2006. B17. K. Ertopcu, Inal M.M., Z. Ozenc, A. Donmez, F. Ozdemir, I. Ozelmas, S. Tınar, “Evaluation of Placental Retentions after 8536 Uterine Evacuations”, The 9th Congress of the European Society of Contraception, İstanbul, Turkey, May 2006. B18. Inal M.M., S. Kose, K. Ertopcu, M.E. Avci, A. Donmez, I. Ergin, I. Ozelmas, S. Tinar, “Vaginal Infections in Family Planning Regular Visitors”, The 9th Congress of the European Society of Contraception, İstanbul, Turkey, May 2006. B19. Inal M.M., S. Kose, K. Ertopcu, F. Demirci, A. Donmez, D. Oztekin, I. Ozelmas, S. Tinar, “Chlamydia: Prevalance Study of Turkish Population”, The 9th Congress of the European Society of Contraception, İstanbul, Turkey, May 2006. B20. Inal M.M., S. Kose, Y. Yildirim, Y. Ozdemir, E. Toz, K. Ertopcu, I. Ozelmas, S. Tinar, “The Relationship between HPV Infection and Cervical Intraepithelial Neoplasia (CIN) in Turkish Women”, 18th FIGO World Congress, Kuala Lumpur, Malaysia, November, 2006. 8 C. Yazılan uluslararası kitaplar veya kitaplarda bölümler: D. Ulusal hakemli dergilerde yayımlanan makaleler: D1. Sancı, M., M.M. İnal, “60 Yaş Üzeri Kadınlarda Jinekolojik Operasyonlar”, Geriatri, 2 (3): 127-131 (1999). D2. Basogul, N., Sanci, M., Tinar, S., Basogul, O., M.M. Inal, “The Importance of Doppler Ultrasonography, Ultrasonographic Morphologic Scores and Ca-125 in Differential Diagnosis of Pelvic Masses”, Gynecol Obstet Reprod Med, 6 (3): 201-204 (2000). D3. Hanhan, M., Vardar, E., Keleş, R., Özbakkaloğlu, A., M.M. İnal, “Evre I İnvaziv Serviks Karsinomları: SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi Deneyimi”, Ege Tıp Dergisi, 39 (1): 51-55 (2000). D4. Maral, İ., M. İnal, Koru, E., Başoğul, N., Başoğul, Ö., “Gebelik ve Adneksial Torsiyon (Olgu Sunumu)”, Ege Tıp Dergisi, 39 (3): 221 – 223 (2000). D5. Sancı, M., M.M. İnal, Güler, A., Özgüder, T., Arıcı, A., İspahi, Ç., Tınar, Ş., “Refrakter Hiperemezis Gravidarum’un Tedavisinde Oral Metilprednisolon’un Yeri”, Klinik Bilimler ve Doktor, 8 (3): 367-370 (2002). D6. M.M. İnal, Sancı, M., Güler, A., Özgüder, T., Arıcı, A., İspahi, Ç., Tınar, Ş., “Endometrial Ablasyon Sonrası Gebelik: Olgu Sunumu”, Klinik Bilimler ve Doktor, 8 (3): 398-400 (2002). D7. Sancı, M., Taner, CE., M.M. İnal, Pilancı, MB., Arıöz, DT., Uysal, A., “Sezeryan Sonrası Ağrı Kontrolünde İnsizyon Öncesi Lokal Anestezinin Etkisi”, Klinik Bilimler ve Doktor, 8 (3): 379-382 (2002). D8. Oner, RS., Sanci, M., Albayram, F., M.M. Inal, Maral, I., “Heterozygous Achondroplasia: Prenatal Diagnosis”, Gynecol Obstet Reprod Med, 9 (1): 44-45 (2003). D9. M.M.İnal, Aydar, GU., Pilancı, MB., İncebıyık, A., Sancı, M., Tınar, Ş., “Gebelik ve Adneksial Torsiyon (Olgu Sunumu)”, MN Klinik Bilimler ve Doktor, 9 (1): 103-105 (2003). 9 D10. Pilancı, MB., İncebıyık, A., Camuzcuoğlu, H., M.M. İnal, Tınar, Ş., İspahi, Ç., “Müllerian Agenezis: 8 Olgu, Sınıflama ve Yaklaşım”, Klinik Bilimler ve Doktor, 10 (5): 600-604 (2004). D11. Karakoç, MK., Gür, EB., Sancı, M., M.M. İnal, Şahin, E., Çelik, E., Kızılyar, A., İmren, A., “Gestasyonel DM’ta Fetal ve Maternal Sonuçlar: OGTT’de Tek Değer Yüksekliğinin İrdelenmesi”, Klinik Bilimler ve Doktor, 11 (1): 87-92 (2005). D12. Sancı, M., Gür, EB., M.M. İnal, Sekü, İ., Şahin, E., Kurtulmuş, S., Boyacıoğlu, H., Kızılyar, A., “Gestasyonel DM Taramasında 50 gr Glukoz Tarama Testinin Etkinliği”, Klinik Bilimler ve Doktor, 11 (1): 83-86 (2005). D13. M.M. İnal, “Bariyer Kontraseptif Yöntemler”, Türkiye Klinikleri Jinekoloji Obstetrik, 2 (22): 41-50 (2006). D14. M. İnal, Yıldırım, Y., Ertopcu, K., Özelmas, İ., Tınar, Ş., “Ege Doğumevi ve Kadın Hastalıkları Eğitim ve Araştırma Hastanesi Aile Planlaması Bölümü’ne 2001-2005 yılları Arasında Başvuran Perimenopozal Kadınlar Tarafından Kullanılan Kontraseptif Yöntemler”, Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi, 7 (2): 013-016 (2006). D15. Naykı, C., M. İnal, Yıldırım, Y., Tınar, Ş. “Preterm Doğum Eyleminin Tedavisinde Nifedipin ile Hidrasyon+Sedasyon’un Karşılaştırılması: Prospektif Klinik Bir Çalışma”, Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi, 8 (1): 23-26 (2007). D16. Balsak, D., M. İnal, Yıldırım Y., Öner, RS., Tınar, Ş., “Rüptüre Olmamış Kornual Gebeliğin Intravenöz Methotrexate ile Başarılı Tedavisi: Olgu Sunumu”, İnönü Üniversitesi Tıp Fakültesi Dergisi, 14 (1): 65-67 (2007). D17. Yıldırım, Y., Balsak, D., M. İnal, Tınar, Ş., “Overin Malign Mikst Mullerian Tümör’ü: Klinikopatolojik Özellikler, Tedavi ve Prognoz”, İnönü Üniversitesi Tıp Fakültesi Dergisi, 14 (1): 37-40 (2007). D18. Sentas, A., M. Inal, Sanci, M., Yildirim, Y., Inan, S., Vatansever, S., Dicle, N., “Immunohistochemical Evaluation of TGF-β Isoforms in Cases with Ovarian Endometriosis and Follicular Cyst”, Gynecol Obstet Reprod Med (GORM), 13 (1): 34-37 (2007). D19. Karalti, O., M. Inal, Yildirim, Y., Çoker, I., Tınar, Ş., “The relationship between maternal 5,10-methylenetetrahydrofolate reductase C677T polymorphism and the development of neural tube defects: a 5-year study in Aegean Obstetrics and Gynecology Training and Research Hospital”, Turkiye Klinikleri J Gynecol Obst, 17 (5): 337-41 (2007). 10 D20. Yildirim, Y., Sonmez, S., Toz, E., M. Inal, Aykas, A., Uslu, A., “Solid Organ (Kidney, Liver, Pancreas-Kidney, Heart, Lung and Heart-lung) Transplantations and Pregnancy”, Marmara Medical Journal, 21 (1); 079-088 (2008). E. Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler: E1. İ. Maral, J. Duran, E. Koru, İnal, M.M., “Gebelik + Adneksial Torsiyon”, Perinatoloji Kongresi, Antalya, 10-13 Mayıs 1998. E2. İ. Maral, Y. Özgenç, İnal, M.M., “Gebelik + Metastatik Ca”, Perinatoloji Kongresi, Antalya, 10-13 Mayıs 1998. E3. İ. Maral, RS. Öner, H. Kanıt, İnal, M.M., “Heterozigos Akondroplazi”, Perinatoloji Kongresi, Antalya, 10-13 Mayıs 1998. E4. İ. Maral, RS. Öner, H. Kanıt, İnal, M.M., “Prenatal USG Teşhis: Fetal Cystic Adenomatoid Malformation (CCAM)”, Perinatoloji Kongresi, Antalya, 10-13 Mayıs 1998. E5. K. Ertopçu, İ. Özelmas, A. Kaçar, O. Alparslan, İnal, M.M., A. Özkutucu, MA. Şanlı, A. Arıcı, “İntraabdominal Rahimiçi Araçların Laparoskopik Çıkarılması (42 Olgunun Değerlendirilmesi)”, 1.Ulusal Aile Planlaması Kongresi, Ankara, 14-17 Nisan 1999. E6. AS. Önoğlu, S. Sadık, E. Turan, O. Alparslan, İnal, M.M., Ç. İspahi, S. Menteşoğlu, “Ofis Laparoskopinin İnfertil Olgularda Rutin Kullanımı”, Türk-Alman Jinekoloji Derneği 3. Jinekoloji ve Obstetrik Kongresi, Antalya, 19-23 Mayıs 1999. E7. CE. Taner, Ö. Başoğul, İnal, M.M., AS. Önoğlu, S. Öztamur, Ş. Tınar, “Anovulatuar Polikistik Overli İnfertil Kadınlarda Düşük Doz Protokol ile uFSH ve rFSH Uygulama Sonuçları”, 21.Yüzyılda Üreme Sağlığı ve Endoskopik Cerrahi Kongresi, Kuşadası, Aydın, 14-17 Eylül 2000. E8. N. Başoğul, M. Sancı, Ö. Başoğul, Ş. Tınar, İnal, M.M., C. Çankaya, “İzole Segmental Jejunal Dilatasyon Nedeniyle Antenatal İntestinal Obstruksiyon Bulgusu: Olgu Sunumu”, 21.Yüzyılda Üreme Sağlığı ve Endoskopik Cerrahi Kongresi, Kuşadası, Aydın, 14-17 Eylül 2000. E9. C. Karanfil, CE. Taner, E. Balık, İnal, M.M., “Genital Prolapsus Tedavisinde Histerektomisiz Cerrahi Yaklaşım”, Türk-Alman Jinekoloji Derneği 4. Kongresi, Antalya, 30 Mayıs – 3 Haziran 2001. 11 E10. M. Sancı, İnal, M.M., A. Güler, Ç. İspahi, Ş. Tınar, “Refrakter Hiperemezis Gravidarum’un Tedavisinde Oral Metilprednisolon’un Yeri”, 3.Ulusal Jinekoloji ve Obstetrik Kongresi, İstanbul, 13-16 Eylül 2001. E11. İnal, M.M., M. Sancı, A. Güler, Ç. İspahi, Ş. Tınar, “Pregnancy After Endometrial Ablation: A Case Report”, 3.Ulusal Jinekoloji ve Obstetrik Kongresi, İstanbul, 13-16 Eylül 2001. E12. S. Sadık, AS. Önoğlu, İnal, M.M., Ç. İspahi, “Ofis Minihisteroskopi Deneyimlerimiz”, 3.Ulusal Jinekoloji ve Obstetrik Kongresi, İstanbul, 13-16 Eylül 2001. E13. M. Hanhan, R. Keleş, A. Güler, İnal, M.M., S. Sayhan, Ş. Tınar, “Uterusta Sınırlı Pozitif Peritoneal Sitolojili Endometrium Kanserlerinde Yaklaşım”, 8.Ulusal Jinekolojik Onkoloji Kongresi, Antalya, 1-5 Mayıs 2002. E14. M. Hanhan, R. Keleş, İnal, M.M., Ş. Tınar, “Borderline Over Tümörleri”, 8.Ulusal Jinekolojik Onkoloji Kongresi, Antalya, 1-5 Mayıs 2002. E15. İnal, M.M., M. Hanhan, ÖF. Demir, Ş. Tınar, “Koriokarsinomlarda SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi Deneyimi”, 8.Ulusal Jinekolojik Onkoloji Kongresi, Antalya, 1-5 Mayıs 2002. E16. AS. Önoğlu, S. Sadık, A. Güler, O. Alparslan, İ. Akın, İnal, M.M., S. Şehirali, İ. Sekü, Y. Yıldırım, “İnfertil Hastalarda Ofis Laparoskopi”, Güncel İnfertilite ve Yardımcı Üreme Teknikleri Sempozyumu, İzmir, 24-27 Nisan 2003. E17. S. Şehirali, S. Özsezgin, İnal, M.M., Ö. Atlı, Y. Yıldırım, C. Naykı, M. Sancı, Ş. Tınar, “Kemoterapi Alan İleri Evre Over Kanserli Hastalarda Rezervuarlı Port Kullanımı ile Konvansiyonel Damar Yolu Kullanımının Randomize Prospektif Çalışması”, 5.Türk-Alman Jinekoloji Derneği ve 2. Reproductive Medicine Tartışmalı Konular ve Çözümler Ortak Kongresi, Antalya, 16-20 Mayıs 2003. E18. K. Ertopçu, BK. Saydam, İnal M.M., A. Dönmez, İ. Ergin, Ş. Vardar, S. Yetkin, İ. Özelmas, “Danışmanlık ve Memnuniyet”, 4.Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi, Ankara, 20-23 Nisan 2005. E19. K. Ertopçu, İnal M.M., Z. Özenç, A. Dönmez, A. Turpçulu, İ. Özelmas, Ş. Tınar, “Aylık Enjektabl Kontraseptiflerin 5 Yıllık Takibi”, 4.Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi, Ankara, 20-23 Nisan 2005. 12 E20. Z. Özenç, İnal M.M., NS. Deniz, A. Dönmez, K. Ertopçu, İ. Özelmas, Ş. Tınar, “Intern Doktorların Aile Planlamasıyla İlgili Teorik Bilgilerinin Değerlendirilmesi”, 4.Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi, Ankara, 20-23 Nisan 2005. E21. Inal, M., Y. Yildirim, A. Incebiyik, M. Sanci, C. Ispahi, “Diagnostic Accuracy of Sonohysterography in the Evaluation of Uterine Cavities in Tamoxifen Administered Asymptomatic Postmenopausal Breast Cancer Patients with Endometrial Thickness ≥5 mm”, 10. Ulusal Jinekolojik Onkoloji Kongresi, Özet Kitabı, 38, Antalya, 2006. E22. İnal, M.M., M. Altındağ, M. Sancı, S. İnan, K. Özbilgin, N. Dicle, S. Sayhan, Y. Yıldırım, C. Ispahi, “Over Tümörlerinde Thomsen-Friedenreich Antijeni’nin İmmunohistokimyasal Olarak İncelenmesi”, 10. Ulusal Jinekolojik Onkoloji Kongresi, Özet Kitabı, 72, Antalya, 2006. E23. D. Balsak, Inal, M.M., Y. Yildirim, RS. Oner, S. Tinar, “Conservative Treatment of Unruptured Cornual Pregnancy Using Double-dose Intravenous Methotrexate: A Case Report”, Türk Jinekoloji ve Obstetrik Derneği Kongresi, Uzmanlık Sonrası Eğitim ve Güncel Gelişmeler Dergisi Kongre Özel Sayısı, 137, Antalya, 2006. E24. A. Sentas, Inal, M., M. Sanci, Y. Yildirim, S. Inan, S. Vatansever, N. Dicle, “Immunohistochemical Evaluation of TGF-β isoforms in Cases with Ovarian Endometriosis and Follicular Cyst”, 2. Ulusal Üreme Endokrinolojisi ve İnfertilite Kongresi (TSRM2006), Kongre Özet Kitabı, 213, Antalya, 2006. F. Uluslararası kitap veya kitaplarda bölümlerin çevirisi: F1. Inal M.M. “Pelvik Cerrahi’nin Psikolojik Yönleri”, In: TeLinde’s Operative Gynecology, ed. Rock JA and Jones HW, Lippincott Williams & Wilkins; 9.Basım Türkçe Çevirisi ed. Tavmergen, E., s23-40, Güven Kitabevi, İzmir, 2005. F2. Inal M.M. “Jinekoloji’de Lazer Uygulaması”, In: TeLinde’s Operative Gynecology, ed. Rock JA and Jones HW, Lippincott Williams & Wilkins; 9.Basım Türkçe Çevirisi ed. Tavmergen, E., s303-330, Güven Kitabevi, İzmir, 2005. F3. Inal M.M. “Meme Hastalıkları: Benign ve Malign” In: TeLinde’s Operative Gynecology, ed. Rock JA and Jones HW, Lippincott Williams & Wilkins; 9.Basım Türkçe Çevirisi ed. Tavmergen, E., s303-330, Güven Kitabevi, İzmir, 2005. 13 G. Uluslararası bilimsel toplantılarda aldığı görevler: G1. Organization Committee Member. 9th Congress of the European Society of Contraception, Istanbul ,Turkey, May 2006. G2. Trainee Committee Member. 14th European Meeting and Exchange Programme of Trainees in Obstetrics and Gynecology. ENTOG (European Network of Trainees in Obstetrics and Gynecology), Ljubljana, Slovenia, Nov 2004. (Davetiye) H. Uluslararası bilimsel toplantılara katılımlar: H1. The 7th Congress of the European Society of Contraception, Genova, Italy, April 1013, 2002. H2. The 5th Congress of the European Society of Gynecology, Rhodes, Greece, October 9-11, 2003. H3. The 8th International Conference “Emerging Technologies in Drug and Gene-based Therapeutics”, Crete, Greece, September 3-10, 2005. H4. The 9th Congress of the European Society of Contraception, Istanbul, Turkey, 3-6 May, 2006. H5. MSD Speaker’s Forum; Leading the Way for Prevention of Cervical Cancer and Beyond, Prag, Chech Republic, 29 February-2 March, 2008. H6. 16th International Meeting of the European Society of Gynaecological Oncology (ESGO) in Belgrade, Serbia October 11 - 14, 2009. I. Uluslararası bilimsel toplantılarda konuşmalar: I1. Inal M.M., “Genetic Evaluation in Habitual Abortions”. Proceedings of the 8th International Conference on “Emerging Technologies in Drug and Gene-based Therapeutics”, p169, Crete, Greece, September 2005. 14 I2. Inal M.M., “Sterilisation”, Meet the Expert Sessions. 9th Congress of the European Society of Contraception, Istanbul, Turkey, May 2006. I3. Inal M.M., “Contraception again with IUD after IUD dislocation and IUD+pregnancy (evaluation of 6412 cases), Free Communication, 9th Congress of the European Society of Contraception, Istanbul, Turkey, May 2006. J. Makale Eleştirmenliği (Reviewer) Yaptığı Uluslararası Dergiler ve Eleştirmenliğini Yaptığı Makaleler: J1. Placenta, “Manufacture of a Cell-Free Amnion Matrix Scaffold That Supports Amnion Cell Outgrowth in vitro”, (PL-05-00099), 2005. J2. Placenta, “15-Deoxy-Δ12,14-Prostaglandin J2 and Triglitazone Regulation of Release of Phospholipid Metabolism, Inflammatory Cytokines and Proteases from Human Gestational Tissues”, (PL-05-90114), 2005. J3. Placenta, “Functional and Molecular Expression of AQP9 Channel and UT-A Transporter in Normal and Preeclamptic Human Placenta”, (PL-05-90083), 2005. J4. Placenta, “Cytotoxic Effect of Zinc-Citrate Compound on Choriocarcinoma Cell line”, (PL-05-90071), 2005. J5. Placenta, “Expression of Kallikrein, Bradykinin B2 Receptor and Endothelial Nitric Oxide Synthase in Placenta in Normal Gestation, Preeclampsia and Placenta Accreta”, (PL-05-90018), 2005. J6. Placenta, “Purinergic Receptor Expression and Activation in First Trimester and Term Human Placenta”, (PL-06-90008), 2006. J7. Placenta, “Human Placenta: A Model for Biomonitoring of Lead and its Association with Preterm Delivery Through the Modulation of Oxidant/Antioxidant Status”, (PL-0690049), 2006. J8. Placenta, “Tumor Necrosis Factor – Alpha Converting Enzyme in the Human Placenta Throughout Gestation”, (PL-06-90091), 2006. J9. Fertil Steril, “Outcome of Preimplantation Genetic Diagnosis in Reciprocal Translocations”, (F&S2341), 2006. 15 J10. Placenta, “Reference Weights for Placentas Delivered before the 28th Week of Gestation”, (PL-07-90004), 2007. J11. Placenta, “Imprinting and Promoter Usage of Insulin-like Growth Factor II in Twin Discordant Placentae”, (PL-07-90045), 2007. J12. Placenta, “Placental anti-oxidant gene polymorphisms, enzyme activity, and oxidative stress in preeclampsia”, (PL-07-90091), 2007. J13. Fertil Steril, “Immunocontraceptive Properties of Recombinant Sperm Protein DE: Implications for the Development of Novel Contraceptives”, (F&S2624), 2007. J14. Fertil Steril, “Estrogen Receptor Alpha Gene Polymorphisms are Associated with Idiopathic Premature Ovarian Failure”, (F&S3366), 2007. J15. Fertil Steril, “Protective effects of amlodipine on ischemia/reperfusion injury of rat ovary: biochemical and histopathologic evaluation”, (F&S4009), 2007. J16. Placenta, “Induction of trophoblast cell fusion by a protein tyrosine phosphatase inhibitör”, (PL-07-90099), 2007. J17. Fertil Steril, “Intercoat Gel (Oxiplex): Efficacy, safety and tissue response in a laparoscopic mouse model”, (F&S5668), 2008. J18. Fertil Steril, “The Contribution of Rescue Spontaneous Maturation in Controlled Ovarian Stimulation Cycles of Poor Responder Patients”, (F&S5775), 2008. J19. Placenta, “Cyclooxygenase-2 derived PGE2 and PGI2 play an important role via EP2 and PPARδ receptors in early steps of oil induced decidualization in mice”, (PL-0890005), 2008. J20. Placenta, “Leptin Stimulates System A Amino Acid Transport: Evidence of a Direct Effect on Human Placental Function”, (PL-08-90002), 2008. J21. Placenta, “Placental weight in mosaic trisomy pregnancies”, (PL-08-90046), 2008. J22. Placenta, “Conditioned medium from human decidual stromal cells has a concentration-dependent effect on trophoblast cell invasion”, (PL-08-90068), 2008. J23. Placenta, “Dietary protein and energy during gestation affects circulating indicators of placental function and fetal development in heifers”, (PL-08-90143), 2008. 16 J24. Fertil Steril, “Variations in folate pathway genes are associated with unexplained female infertility”, (F&S6530), 2009. J25. Fertil Steril, “Evidence of prokineticin dysregulation in Fallopian tube from women with ectopic pregnancy”, (F&S7778), 2009. J26. Gyn Oncology, “The association between metabolic abnormality and endometrial cancer: a large case-control study in China”, (GYN-09-1050), 2009. J27. Gyn Oncology, “A global review of age-specific and overall prevalence of cervical precancerous lesions”, (GYN-09-1135), 2009. J28. Placenta, “CFTR may modulate AQP9 functionality in preeclamptic placentas”, (PL09-90021), 2009. J29. Placenta, “High Saturated Fat Diet Induces Gestational Diabetes and Placental Vasculopathy in C57BL/6 Mice”, (PL-09-90065), 2009. J30. Placenta, “Dexamethasone stimulates placental system A transport and trophoblast differentiation in term villous explants”, (PL-09-90113), 2009. J31. Placenta, “Proteases and sFlt-1 release in the human placenta”, (PL-10-90003), 2010. J32. Fertil Steril, “Increased viability of endometrial cells by in vitro treatment with di(2-ethylhexyl) phthalate”, (F&S8839), 2010. K. Ulusal bilimsel toplantılarda aldığı görevler: K1. İnal M.M., “Adolesan Jinekolojisi – Vajinal Enfeksiyonlar” (Konuşma): İzmir Türk Jinekoloji ve Obstetrik Derneği Eğitim Toplantısı, İzmir, 18 Ocak 2002. K2. İnal M.M., “Ciltaltı İmplant Uygulamaları” (Konuşma): Celal Bayar Üniversitesi Mezuniyet Sonrası Eğitim Toplantısı, Manisa, 30 Nisan 2003. K3. İnal M.M., “Gebelik Önleyici Yöntemler ve Yenilikler” (Konuşma): 2. Ulusal Hemşirelik Kongresi, İzmir, 15 Mayıs 2003. K4. İnal M.M., “Sağlık Bakanlığı İmplant Kontrasepsiyon Türkiye Pilot Uygulamasının 1 Yıllık Sonuçları Paneli” (Panelist): 4. Ulusal Jinekoloji ve Obstetrik Kongresi, Antalya, 2025 Nisan 2004. 17 K5. İnal M.M., 5. Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi (Davetli Konuşmacı), 19-22 Nisan 2007. K6. İnal M.M., 5. Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi (Danışma Kurulu Üyeliği), 19-22 Nisan 2007. K7. İnal M.M., 2. Güncel Üreme Endokrinolojisi, YÜT Kongresi ve 1. Üreme Tıbbı Derneği Kongresi (Ulusal Bilimsel Kurul Üyeliği), 17-20 Nisan 2008. L. Atıflar: L1. (A2). Taskin, O., Onoglu, A., M. Inal, Turan, E., Sadik, S., Vardar, E., Postaci, H., Wheeler J.M., “Long-term Histopathologic and Morphologic Changes after Thermal Endometrial Ablation. J Am Assoc Gynecol Laparosc, 9 (2): 186-190, (2002). L1.1. Dan Y., Yat-May W., Ying C., Enlan X., Tin-Chiu L., “Asherman syndrome— one century later”, Fertility and Sterility, 89 (4): 759–779 (2008). L1.2. Nappi, C., Di Spiezio, A., Greco, E., Guida, M., Bettocchi, S., Bifulco, G., “Prevention of adhesions in gynaecological endoscopy”, Human Reproduction Update, 13 (4): 379–394 (2007). L1.3. McCausland, AM., McCausland, VM., “Long-term complications of endometrial ablation: Cause, diagnosis, treatment, and prevention”, Journal of Minimally Invasive Gynecology, 14 (4): 399–406 (2007). L1.4. Mukul, LV., Linn, JG., “Pregnancy complicated by uterine synechiae after endometrial ablation”, Obstet Gynecol, 105 (5 Pt 2): 1179-82 (2005). L1.5. Shaamash, AH., Sayed, EH., “Prediction of successful menorrhagia treatment after thermal balloon endometrial ablation”, Journal of Obstetrics and Gynaecology Research, 30 (3): 210–216 (2004). L1.6. Liha, L., Huiyi H., Jiali, K., Linghong, D., “Thermal Balloon Endometrial Clinical Study of Therapy for the Treatment of Menorrhagia”, China Practical Gynaecology and Obstetrics, (2003). L1.7. Onoglu, A., Taskin, O., Inal, M., Sadik, S., Simsek, M., Akar, M., Kursun, S., Ispahi, C., “Comparison of the Long-term Histopathologic and Morphologic 18 Changes after Endometrial Rollerball Ablation and Resection: A Prospective Randomized Trial”, The J Min Inv Gyn, 14 (1): 39-42, (2007). L1.8. Wyss, P., Caduff, R., Tadir, Y., Degen, A., Wagnières, G., Schwarz, V., Haller, U., Fehr, M., “Photodynamic Endometrial Ablation: Morphological Study”, Lasers in Surgery and Medicine, 32 (4): 305–309 (2003). L1.9. Hua, D., Yanjie, L., Lng, L., Yi, Y., Enlan, X., “Research on repairing patterns and factors causing subsequent surgery after trancervical resection of endometrium”, Chinese Journal of Obstetrics and Gynaecology, 38 (12): (2003). L1.10. Laberge, PY., “Serious and deadly complications from pregnancy after endometrial ablation: Two case reports and review of the literatüre”, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 37 (6): 609–613, (2008). L1.11. Enlan, X., “Removal of Second Generation of Endometrium”, Chinese Journal of Obstetrics and Gynaecology, 39 (12): (2004). L1.12. Geping, Y., Tong-Yu, Z., Ming, C., Shujun, Y., “Long-term Effect on Radiofrequency Heat-Coagulation Endometrial Ablation in the Treatment of Anovulatory Dysfunctional Uterine Bleeding”, Chinese Journal of Obstetrics and Gynaecology, 9 (3): 73-75 (2011). L1.13. Feng, L., Gao, W., Yang, B., Wang, W., Zhao, W., Wei, L., “Clinical Analysis of Abnormal Uterine Bleeding Treatment with Thermablate EAS”, Journal of Peking University (Health Sciences), 38 (4): 432-435 (2006). L1.14. McCausland, AM., McCausland, VM., “Long-Term Complications of Minimally Invasive Endometrial Ablation Devices”, Journal of Gynecologic Surgery, 26 (2): 133-149 (2010). L1.15. Ahonkallioa, SJ., Liakkab, AK., Martikainena, HK., Santalaa, MJ., “Feasibility of endometrial assessment after thermal ablation”, European Journal of Obstetrics & Gynecology and Reproductive Biology, 147 (1): 69-71 (2009). L1.16. Brun, JL., Galant, C., Delvaux, D., Lemoine, P., Henriet, P., Courtoy, PJ., Marbaix, E., “Menstrual activity of matrix metalloproteinases is decreased in endometrium regenerating after thermal ablation”, Hum. Reprod, 24 (2): 333340 (2009). L1.17. Geping, Y., Ming, C., Tong Yu, Z., Xiaoli, Z., “The mechanism of two newly developed endometrial ablation procedures using radiofrequency 19 thermocoagulation for the treatment of dysfunctional uterine bleeding”, Chinese Journal of Obstetrics and Gynaecology, 12 (6): (2011). L1.18. Yujie, L., Sufang, S., Yanmin, W., “Influence of Progesterone On Expression of EGFR、VEGF and KDF after Endometrectomy”, Applied Journal of General Practice, 3 (1): (2008). L1.19. Jialing, T., Suhua, X., Ye, M., Xiuxing, Z., “The clinical analysis of thermal balloon endometrial ablation on 30 cases with menorrhagia”, Guangzhou Medical Journal, 37 (6): (2006). L1.20. Gepin, Y., Zu, LJ., Yu T., Ming, C., “Estrogen receptor and progesterone receptor expression and mechanism of endometrium of anovulatory dysfunctional uterine bleeding treated with Radiofrequency heat-coagulation”, Chinese Journal of Clinical Medicine for Women and Children, 12 (1): 175-181 (2010). L1.21. Qin, T., Volt, LX., “Thermal Balloon Method Combined with Drug Treatment of Menorrhagia”, Journal of Shanxi Medical University, 37 (5): 544-545 (2006). L1.22. Hui, X., “Non-Hysteroscopic Endometrial Surgery”, Foreign Medical Sciences (Obstet-Gynecol Fascicle), 29 (4): (2002). L1.23. Dan, Z., Yandang, L., Yan, M., Lin, Z., “Ultrasonographic evaluation of uterine hemodynamics following transcervical resection of endometrium”, Chinese Journal of Medical Ultrasonography, 2 (1): (2005). L1.24. Mishra, K., Manucha, V., Sengupta, R., Singh, K., Aggarwal, N., “Cytomorphology and Histomorphology After Thermal Endometrial Ablation”, Acta Cytologica 47 (6): 1001-1007 (2003). L1.25. Yujie, L., Sufang, S., “Endometrial resection assisted with clinical observation of methyl-hydroxyprogesterone”, Shandong Medical Journal, 12 (3): (2006). L1.26. Lei, Z., Yan, D., Ma, J., Wang, F., Buaijiaer, J., “Resection of endometrium for endometrial atypical hyperplasia clinical observation of 28 cases”, Journal of Xinjiang Medical University, p. 1384-1386 (2011). L1.27. Avci, ME., Sadik S., Uçar MG., “A Prospective Study of Rollerball Endometrial Ablation in the Management of Refractory Recurrent Symptomatic 20 Endometrial Hyperplasia without Atypia”, Gynecol Obstet Invest, 74 (4): 282–287 (2012). L1.28. Izue, C., “Clinical study on treatment of dysfunctional uterine bleeding with Thermal balloon endometrial removal”, Chinese Journal of Rural Medicine and Pharmacy, 8 (3): (2005). L1.29. Geping, Y,, Tongyu, Z., Juan, L., Ming, C., Shujun, Y., Xiaoli, Z., “Decreased expression of survivin, estrogen and progesterone receptors in endometrial tissues after radiofrequency treatment of dysfunctional uterine bleeding”, World Journal of Surgical Oncology, 10 (1): 100 (2012). L1.30. Alhilli, MM., Wall, DJ., Brown, DL., Weaver, AL., Hopkins, MR., Famuyide, AO., “Uterine ultrasound findings after radiofrequency endometrial ablation: correlation with symptoms”, Ultrasound Quarterly, 28 (4): 261-268 (2012). L1.31. Hongxiu, L., Qingling, Y., “Vacuum thermal balloon treatment for menopausal transitional dysfunctional uterine bleeding”, Chinese Community of Physicians, 9 (12): (2010). L1.32. Yan, D., “The guiding significance of Caspase-3 in patients with hydatidiform mole before they reproduce”, Journal of Xinjiang Medical University, p. 1387-1389 (2011). L1.33. Gimpelson, RJ., Bieber, EJ., Loffer, FD., "The role of repeat procedures and second-look hysteroscopes in endometrial ablation/resection", Gynecologic Hysteroscopy, Resectoscopy and Endometrial Ablation p.201 (2003). L1.34. Chunfang, L., “Peri-menopausal dysfunctional uterine bleeding treatment”, Chinese Medicine of Factory and Mine, 19 (2): (2006). L1.35. Park, H., Seong, SJ., Yoon, BS., “The effect of operative hysteroscopy conducted before progestin treatment in early stage endometrial cancer from the view of fertility”, Gynecol Oncol, 123 (2): 427-8 (2011). L1.36. Ahonkallio, S., “Endometrial Thermal Ablation”, Acta Universitatis Ouluensis D Medica, 1205, (2013). L1.37. Xiaolin, LV., “TB-endometrium study and clinical application of therapy for the treatment of dysfunctional uterine bleeding”, Journal of Maternal and Child Healthcare of China, 2 (1): (2011). 21 L1.38. Qingfen, Y., Aiqin, Y., Shehong, H., “Hysteroscope in treating submucosal myoma of uterus, uterine SEPTA and clinical analysis of intrauterine foreign body”, Chinese Journal of Traditional Chinese and Western Medicine, 11 (5): (2004). L1.39. Yujie, L., Sufang, S., “Effect of progesterone on endometrial EGFR, KDR and VEGF expression after TRCE”, Shandong Medical Journal, 15 (4): (2008). L1.40. Simionescu, C., Margaritescu, CL., Stepan, A., Ciurea, R., Cernea, N., “Uterine pseudotumors”, Rom J Morphol Embryol, 52 (3): 743–758 (2011). L1.41. Clark, JT., Dupuch, L., Balchin, I., Byrne, DL., Frappell, JM., “Variable pressure cornual resection. Does radical hysteroscopic surgery give better results?”, Gynecological Surgery, 3 (3): 180-185 (2006). L1.42. Chunxia, D., Guang, S., Liya, G., “Clinical study on climacteric dysfunctional uterine bleeding treated with thermal balloon endometrial ablation and hysteroscopic endometrial electroresection”, Journal of Maternal and Child Healthcare of China, 26 (36): (2011). L1.43. Qin, Y., “Care for Metropathia Hemorrhagica Patients Receiving Thermal Endometrial Ablation: A report of 51 cases”, Chinese Journal of General Practice, 12 (17): (2009). L1.44. Qiumeini, L., Tang, Q., “Perimenopausal endometrial disease combined with TCRE-hydroxyprogesterone treatment efficacy”, China Foreign Medical Treatment, 31 (11): (2012). L1.45. Duleba, AJ., "Pediatrics Ob/GYN Family Practice Business of Healthcare" (2004). L1.46. Bruno, R., and D. E. Townsend. "Hysteroscopic Evaluation Following Endometrial Ablation", (2004). L1.47. Duleba, A.J., “What do Endometrial Cryoablation and Cryomyolysis have to Offer?”, Contemporary Ob/Gyn, 50 (3): 56-65 (2005). L1.48. El-Saman, A., Mohammad, HSE., Zakhera, MS., Zahran, KM., Ahmad, EM., Salem, AO., “Tactile Electrosurgical Ablation: A New Technique for Endometrial Ablation-A Preliminary Study”, Med. J. Cairo Univ, 78 (1): 241-246 (2010). 22 L2. (A24). M.M. Inal, Kose, S., Yildirim, Y., Ozdemir, Y., Toz, E., Ertopcu, K., Ozelmas, I., Tinar, S., “The Relationship Between HPV Infection and Cervical Intraepithelial Neoplasia (CIN) in Turkish Women”, Int J Gynecol Cancer, 17 (6): 1266–1270 (2007). L2.1. Dursun, P., Altuntaş, B., Kuşçu, E., Ayhan, A., “Women's knowledge about human papillomavirus and their acceptance of HPV vaccine”, Australian and New Zealand Journal of Obstetrics and Gynaecology, 49 (2): 202–206 (2009). L2.2. Dursun, P., Senger, SS., Arslan, H., Kuşçu, E., Ayhan, A., “Human papillomavirus (HPV) prevalence and types among Turkish women at a gynecology outpatient unit”, BMC Infectious Diseases, 9: 191 (2009). L2.3. Usubütün, A., Alemany, L., Küçükali, T., Ayhan, A., Yüce, K., de Sanjosé, S., Font, R., Lloveras, B., Klaustermeier, J., Quint, W., Muñoz, N., Bosch, FX., “Human papillomavirus types in invasive cervical cancer specimens from Turkey”, Int J Gynecol Pathol, 28 (6): 541-8 (2009). L2.4. Yılmaz, HH., Yazıhan, N., Tunca, D., Sevinç, A., Olcayto, EO., Özgül, N., Tuncer, M., “Cancer Trends and Incidence and Mortality Patterns in Turkey”, Jpn. J. Clin. Oncol, 41 (1): 10-16 (2011). L2.5. Darnel, AD., Wang, D., Ghabreau, L., Yasmeen, A., Sami, S., Akil, N., Al Moustafa, AE., “Correlation between the presence of high-risk human papillomaviruses and Id gene expression in Syrian women with cervical cancer”, Clinical Microbiology and Infection, 16 (3): 262–266 (2010). L2.6. Yavuzer, D., Karadayi, N., Salepci, T., Baloglu, H., Dabak, R., Bayramicli, OU., “Investigation of human papillomavirus DNA in colorectal carcinomas and adenomas”, Medical Oncology, 28 (1): 127-132 (2011). L2.7. Eren, F., Erenus, M., Bas, E., Ahiskali, R., Yoldemir, T., “Prevalence of HPV infection by cytologic diagnosis and HPV DNA extraction and prevalence of the HPV genotypes detected in urban Turkish women”, International Journal of Gynecology & Obstetrics, 109 (3): 235–238 (2010). L2.8. Durusoy, R., Yamazhan, M., Taşbakan, MI., Ergin, I., Aysin, M., Pullukçu, H., Yamazhan, T., “HPV Vaccine Awareness and Willingness of First-Year Students Entering University in Western Turkey”, Asian Pacific J Cancer Prev, 11: 1-6 (2010). 23 L2.9. Mehmetoglu, HC., Sadikoglu, G., Ozcakir, A., Bilgel, N., “Pap smear screening in the primary health care setting: A study from Turkey”, N Am J Med Sci, 2 (10): 467–472 (2010). L2.10. Bayram, A., Erkılıç, S., Balat, Ö., Ekşi, F., Gürol, M., Öztürk, E., Kaya, G., “Prevalence and genotype distribution of human papillomavirus in non-neoplastic cervical tissue lesion: Cervical erosion”, Journal of Medical Virology, 83 (11): 1997–2003 (2011). L2.11. Atilgan, R., Celik, A., Boztosun, A., Ilter, E., Yalta, T., Ozercan, R., “Evaluation of cervical cytological abnormalities in Turkish population”, Indian J Pathol Microbiol, 55 (1): 2-5 (2012). L2.12. Seoud, M., “Burden of human papillomavirus-related cervical disease in the extended middle East and north Africa-a comprehensive literature review”, J Low Genit Tract Dis, 16 (2): 106-20 (2012). L2.13. Yavuzer, D., Salepci, T., Karadayi, N., Baloglu, H., Kucukodaci, Z, “Human papillomavirus is not associated with breast carcinoma”, Breast Cancer Research and Treatment, 122 (3): 899-900 (2010). L2.14. Yuce, K., Pinar, A., Salman, MC., Alp, A., Sayal, B., Dogan, S., Hascelik, G., “Detection and genotyping of cervical HPV with simultaneous cervical cytology in Turkish women: a hospital-based study”, Archives of Gynecology and Obstetrics, 286 (1): 203-208 (2012). L2.15. Vaccarella, S., Bruni, L., Seoud, M., “Burden of Human Papillomavirus Infections and Related Diseases in the Extended Middle East and North Africa Region”, Vaccine, 31 (6): 32–44 (2013). L2.16. Karadayi, N., Gecer, M., Kayahan, S., Yamuc, E., Onak, NK., Korkmaz, T., Yavuzer, D., “Association between human papillomavirus and endometrial adenocarcinoma”, Medical Oncology, 30: 597 (2013). L2.17. Demir, ET., Ceyhan, M., Simsek, M., Gunduz, T., Arlier, S., Aytac, R., Aycan, AE., Gurbuz, V., “The prevalence of different HPV types in Turkish women with a normal Pap smear”, Journal of Medical Virology, 84 (8): 1242–1247 (2012). 24 L2.18. Dursun, P., et al. “HPV Types in Turkey: Multicenter Hospital Based Evaluation of 6388 Patients in Turkish Gynecologic Oncology Group Centers”, Turkish Journal of Pathology, 29 (3): 210–216 (2013). L2.19. Ozdaş, S., Bozdayı, G., Demirağ, A., Onan, A., Taşkıran, C., Ilhan, MN., “Diagnosing Human Papillomavirus and Human Papillomavirus Type 16 by Realtime PCR in Patient Undergone to Colposcopy and Significance of the Diagnosis”, J Turk Soc Obstet Gynecol, 10: 79-89 (2013). L2.20. Tuncer, M., ed. “Türkiye'de Kanser Harcamaları ve Maliyet Etkinlik Çalışmaları”, TC Sağlık Bakanlığı, (2009). L2.21. Ozyer, S., Uzunlar, O., Ozler, S., Kaymak, O., Baser, E., Gungor, T., Mollamahmutoglu, L., “Awareness of Turkish Female Adolescents and Young Women about HPV and their Attitudes Towards HPV Vaccination”, Asian Pac J Cancer Prev, 14 (8): 4877-4881 (2013). L2.22. Mehmetoğlu, HC., et al. "Screening for Cervical Cancer with Pattern of Pap Smear. A Study among Married Women Attended to a Primary Health Care Unit in Turkey." N Am J Med Sci, 2 (10): 467-72 (2010). L2.23. Altun, Z., Yarkın, F., Vardar, MA., Uğuz, AH., “The Prevalence of Human Papilloma Virus Infection Among Women who Admitted to Çukurova University Faculty of Medicine Hospital”, Turkiye Klinikleri J Med Sci, 31 (2): 307-14 (2011). L2.24. Tonguc, E., Gungor, T., Var, T., Kavak, E., Yucel, M., Uzunlar, O., “Knowledge about HPV, relation between HPV and cervix cancer and acceptance of HPV vaccine in women in eastern region of Turkey”, J Gynecol Oncol, 24 (1): 713 (2013). L2.25. Ersan, G., Kose, S., Senger, SS., Gunes, H., Sehirali, S., Gurbuz, I., “The Prevalence and Risk Factors of Human Papillomavirus in Female Sex Workers”, Eurasian Journal of Medicine, 45: 16-20 (2013). L2.26. Yavuzer, D., Karadayı, N., Erdağlı, A., Salepçi, T., Baloğlu, H., Dabak, R., “Serviks Kanseri ve Prekanseröz Lezyonlarında PCR ile HPV Tiplemesi”, Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, XX (1): 1-6 (2009). L2.27. Özalp, SS., Us, T., Arslan, E., Öge, T., Kaşifoğlu, N., “HPV DNA and Pap smear test results in cases with and without cervical pathology”, J TurkishGerman Gynecol Assoc, 13: 8-14 (2012). 25 L2.28. Akyar, I., Aydın, Ö., Yakıcıer, M., Tanıl, Z., “Human Papillomavirus prevalence and type in liquid-based cervical samples from Turkish women in a selected risk group”, Turkish Journal of Medical Sciences, 43 (6): 963-970 (2013). L2.29. Özcan, ES., Taşkin, S., “High-risk human papilloma virus prevalence and its relation with abnormal cervical cytology among Turkish women”, Journal of Obstetrics and Gynaecology, 31 (7): 656-658 (2011). L2.30. Ardıç, N., Ozturk, O., Ergünay, K., Sezer, O., “Servikal Sürüntü Örneklerinde Yüksek Riskli İnsan Papilloma Virus Tiplerine Ait E6/E7 mRNA’larının Ticari Otomatize Bir NASBA Sistemiyle Araştırılması”, Mikrobiyol Bul, 43: 463-469 (2009). L2.31. Özgün, G., Aydoğdu, G., “Distribution of Uterin Cervical Lesions and Relation Between Age and Parity Rates in the Mardin Province”, Turkish Journal of Pathology, 29 (1): 46–50 (2013). L2.32. Eren, H., Özgüneş, N., Bayram, Y., Güzin, K., Parlak, M., “Serviksin Prekanseröz Lezyonlarında Human Papilloma Virus (HPV) Tiplerinin Belirlenmesi”, Van Tıp Dergisi, 20 (2): 70-75 (2013). L2.33. Cilli, M., Methiyev, S., Şimşek, A., Kadıoğlu, A., “Cinsel yol ile bulaşan hastalıklar”, Androloji Bülteni, 42 (3): 167-174 (2010). L2.34. Güdücü, N., Gönenç, G., İşçi, H., Yiğiter, AB., Dünder, İ., “Awareness of human papilloma virus, cervical cancer and HPV vaccine in healthcare workers and students of medical and nursing schools”, J Clin Exp Invest, 3 (3): 318-325 (2012). L2.35. Altun, Z., “Çukurova Bölgesindeki Kadınlarda Genital Human Papillomavirus İnfeksiyon Prevalansı”, Çukurova Üniversitesi Mikrobiyoloji Bilim Dalı, Doktora Tezi (2009). L2.36. Karabulut, Y., Dölek, Y., Kurşun, N., "Documentation of cervical cytological findings in Çankırı population." Cumhuriyet Medical Journal (CMJ), 34 (4): 441446 (2012). 26 L3 (A13). Yildirim, Y., M.M. Inal, Tinar, S., “Reproductive and Obstetric Characteristics of Adolescent Pregnancies in Turkish Women”, J Pediatr Adolesc Gynecol, 18 (4): 249253 (2005). L3.1. Usta, IM., Zoorob, D., Abu-Musa, A., Naassan, G., Nassar, AH., “Obstetric outcome of teenage pregnancies compared with adult pregnancies”, Acta Obstetricia et Gynecologica Scandinavica, 87 (2): 178-183 (2008). L3.2. Magalhães, MLC., Furtado, FM., Nogueira, MB., “Precocious and late pregnancy in adolescents – is there a difference comparing the obstetric risks?”, Rev Bras Ginecol Obstet, 28 (8): 443-446 (2006). L3.3. Rocha, RCL., Souza, E., Guazzelli, CAF., Filho, AC., Soares, EP., Nogueira, ES., “Prematurity and low weight of newborns from primiparous adolescents according to age groups”, Rev Bras Ginecol Obstet, 28 (9): 530-5 (2006). L3.4. Briggs, MM., Hopman, WM., Jamieson, MA., “Comparing pregnancy in adolescents and adults: obstetric outcomes and prevalence of anemia”, J Obstet Gynaecol Can, 29 (7): 546-55 (2007). L3.5. Kuo, CP., Lee, SH., Wu, WY., Liao, WC., Lin, SJ., Lee, MC., “Birth outcomes and risk factors in adolescent pregnancies: Results of a Taiwanese national survey”, Pediatrics International, 52 (3): 447–452 (2010). L3.6. Rocha, RCL., Souza, E., Soares, EP., Nogueira, ES., Filho, AC., Guazzelli, CAF., “Prematurity and Low Birth Weight among Brazilian Adolescents and Young Adults”, Journal of Pediatric and Adolescent Gynecology, 23 (3): 142–145 (2010). L3.7. Duvan, CI., Turhan, NÖ., Onaran, Y., Gümüş, II., Yuvacı, H., Gözdemir, E., “Adolescent Pregnancies: Maternal and Fetal Outcomes”, The New Journal of Medicine, 27: 113-116 (2010). L3.8. Arkan DC., Kaplanoğlu, M., Kran, H., Ozer, A., Coskun, A., Turgut, E., “Adolescent pregnancies and obstetric outcomes in Southeast Turkey: data from two regional centers”, Clinical and experimental obstetrico & gynecology, 37 (2): 144-147 (2010). L3.9. Ünalan, PC., Kaya, ÇA., Akgün, T., Yıkılkan, H., Isgör, A., “Birinci Basamakta Ergen Sağlığına Yaklaşım”, Turkiye Klinikleri J Med Sci, 27: 567-576 (2007). 27 L3.10. Atchara, C., Hornboonherm, P., "Comparative Study in Perception of Unwanted Pregnancy between Secondary School and Undergraduate Students." International Conference, Faculty of Nursing. Mahasarakham University, Thailand (2010). L3.11. Uzun, AK., Orhon, FS., Baskan, S., Ulukol, B., “A comparison between adolescent mothers and adult mothers in terms of maternal and infant outcomes at follow-ups”, Journal of Maternal-Fetal and Neonatal Medicine, 26 (5): 454-458 (2013). L3.12. Karabulut, A., Ozkan, S., Bozkurt, AI., Karahan, T., Kayan, S., “Perinatal outcomes and risk factors in adolescent and advanced age pregnancies: Comparison with normal reproductive age women”, Journal of Obstetrics & Gynaecology, 33 (4): 346-350 (2013). L3.13. Demirgöz, M., Canbulat, N., “Adölesan Gebelik”, Turkiye Klinikleri J Med Sci, 28 (6): 947-52 (2008). L3.14. Mitin, MY., “Prevalence and incidence of gynaecological structure in adolescence”, Russian State Medical University, Graduate Thesis (2005). L3.15. Suwannobol, N., Chobkhayan, S., “Outcomes of Teenage Mothers at Dankhunthot Hospital, Nakhon Ratchasima”, World Academy of Science, Engineering and Technology, 71: 409-411 (2012). L3.16. Taminato, M., Saconato, H., Fram, DS., Dulce, AB., “Screening strategies for GBS during prenatal care for the prevention of early-onset infection: systematic review and meta-analysis”, 12th International Nursing Research Conference, Evidence based practice, session 19, Spain, 2008. L3.17. Col-Araz, N., “Evaluation of factors affecting birth weight and preterm birth in southern Turkey”, JPMA, 63 (4): 459-462 (2013). L3.18. Yıldızhan, R., Kolusarı, A., Edirne, T., Adalı, E., Erol, Ş., Kurdoğlu, M., Kurdoğlu, Z., “Van Yöresinde Adolesan Gebeliklerin Analizi”, Van Tıp Dergisi, 16 (4): 124-127 (2009). L3.19. Rezavand, N., Zangane, M., Khosravi, M., Rezaee, M., “A comparative study of pregnancy results in adolescents and young mothers referred to the Motazedi hospital in Kermanshah”, Journal of Urmia Nursing and Midwifery Faculty, 7 (3): 191-192 (2009). 28 L3.20. Lezcano, SAS., Arce, MSV., Sodero, H., “Comparative study of low-birth weight, 1st minute to depression and termination cesarean between adolescent motherrs and general population”, Revista de Posgrado de la VIa Cátedra de Medicina, 150: 1-3 (2005). L4. (A23). Onoglu, AS., Taskın, O., M. Inal, Sadik S., “Comparison of the Long Term Histopathologic and Morphologic Changes after Endometrial Roller-ball Ablation and Resection: A Prospective Randomized Trial”, The J Min Inv Gyn, 14 (1): 39-42 (2007). L4.1. Ahonkallio, SJ., Liakka, AK., Martikainen, HK., Santala, MJ., “Feasibility of endometrial assessment after thermal ablation”, European Journal of Obstetrics & Gynecology and Reproductive Biology, 147 (1): 69-71 (2009). L4.2. Sharp, HT., “Endometrial ablation: postoperative complications”, American Journal of Obstetrics & Gynecology, 207 (4): 242-247 (2012). L4.3. Stetkiewicz, T., Stachowiak, G., Surkont, G., et al. “Hysteroscopy use in modern diagnostics and therapy”, Przegląd Menopauzalny, 3: 173–176 (2007). L4.4. Yanna, L., Zhang, T., Tao, L., “Long-Term Efficacy and Safety of Thermal Balloon Endometrial Ablation for Patients with Menorrhagia”, Chinese Journal of Minimally Invasive Surgery, 9: (2009). L4.5. Xiao, L., Yan, L., Zhijun, J., Lamei, H., Jing, C., “Radiofrequency induced thermal endometrial ablation in treatment of menorrhagia: a 2 years follow-up”, Shanghai Medical Journal, 31 (5): 320 (2008). L4.6. Maia, HJ., Haddad, C., Casoy, J., Maia, R., Pinheiro, N., Coutinho, EM., “Effect of a hormone-releasing intrauterine system (Mirena®) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection”, Int J Womens Health, 4: 175–183 (2012). L4.7. Guizhi, L., Bin, L., Jinghua, S., “Clinical study on dysfunctional uterine bleeding treated with uterine thermal balloon”, Maternal and child health care of China, 34: (2010). 29 L4.8. Avci, ME., Sadik, S., Uçar, MG., “A Prospective Study of Rollerball Endometrial Ablation in the Management of Refractory Recurrent Symptomatic Endometrial Hyperplasia without Atypia”, Gynecol Obstet Invest, 74 (4): 282–287 (2012). L4.9. Ming, W., “The History, Situation and Future of Hysteroscopic Endometrial Ablation”, Journal Of International Obstetrics And Gynecology, 39 (5): (2012). L4.10. Alhilli, MM., Wall, DJ., Brown, DL., Weaver, AL., Hopkins, MR., Famuyide, AO., “Uterine ultrasound findings after radiofrequency endometrial ablation: correlation with symptoms”, Ultrasound Quarterly, 28 (4): 261-268 (2012). L4.11. Dan, H., Ming-guo, T., Yi, Q., Dong-liang, Y., Wei-bing, S., “Elimination of high-risk elderly patients with acute cholecystitis under the fistula endoscopy via gallbladder mucosa”, Chinese Journal of Endoscopy, 18 (1): (2012). L4.12. Wei-lan, X., Guang-liang, Z., Xiao-li, Z., Li-ping, H., Jing-yu, HE., Shi-jiao, C., ” Retrospective analyse of climacteric dysfunctional uterine bleeding treated with TCRE and TBEA”, The Journal of Practical Medicine, 28 (21): (2012). L4.13. Pérez-López, R., Simoncini, T., Tremollieres, F., Rees, M., Ulrich, LG., “EMAS clinical guide: Assessment of the endometrium in peri and postmenopausal women”, Maturitas, 75 (2): 181-190 (2013). L4.14. Liping, H., Fengbin, J., Ling, Z., “Third generation thermal balloon endometrial therapy for the treatment of dysfunctional uterine bleeding: analysis of 51 cases”, Chinese Journal of Misdiagnostics, 12 (5): (2012). L4.15. Bin, L., Jinghua, S., Mei, W., Hua, L., “Comparative study on Nuoshu (NovaSure) with thermal balloon for the treatment of abnormal uterine bleeding”, Chinese Journal of Obstetrics and Gynecology, 47 (3): (2012). L4.16. Ahonkallio, S., “Endometrial thermal ablation”, ACTA, Universitatis Ouluensis, D 1205, Oulu (2013). L4.17. Xiaoqin, X., Haiyan, S., Hongmei, Z., Guorong, X., “Resection of endometrium in treatment of abnormal uterine bleeding: analysis of 38 cases”, Clinical Medicine of China, 29: (2013). 30 L4.18. Holt, R., Santiago-Muñoz, P., Nelson, DB., Twickler, D., “Sonographic findings in two cases of complicated pregnancy in women previously treated with endometrial ablation”, J. Clin. Ultrasound, 41 (9): 566–569 (2013). L4.19. Zeng-zhen, L., Ju-jie, D., “Radiofrequency ablation in treatment of abnormal uterine bleeding in 82 Cases”, Practical Journal of Clinical Medicine, 10 (5): (2013). L4.20. Chun-Xia, D., Guang, S., Li-Ya, G., “Clinical study on climacteric dysfunctional uterine bleeding treated with thermal balloon endometrial ablation and hysteroscopic endometrial electroresection”, Maternal and Child Health Care of China, 26 (36): (2012). L4.21. Mingguo, T., Yunjuan, Q., Dan, H., Xinyuan, W., “Gallbladder Mucosal Ablation by Hysteroscopic Rollerball Electrocoagulation after Cholecystostomy”, Chinese Journal of minimally invasive surgery, 8 (12): (2008). L4.22. Dreisler, E., Poulsen, L.G., Antonsen, S.L., et al, “EMAS clinical guide: assessment of the endometrium in peri and postmenopausal women”, Maturitas, 75 (2): 181–190, (2013). L5. (A19). M.M. Inal, Yildirim, Y., Taner, CE., “Comparison of the Clinical Efficacy of Flutamide and Spironolactone plus Diane 35 in the Treatment of Idiopathic Hirsutism: A Randomized Controlled Study”, Fertil Steril, 84 (6): 1693-1697 (2005). L5.1. Martin, KA., Chang, RJ., Ehrmann, DA., Ibanez, L., et al. “Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline”, The Journal of Clinical Endocrinology & Metabolism, 93 (4): 1105-1120 (2008). L5.2. Blume-Peytavi, U., Hahn, S., “Medical treatment of hirsutism”, Dermatologic Therapy, 21 (5): 329–339 (2008). L5.3. Radosh, L., “Drug Treatments for Polycystic Ovary Syndrome”, American Family Physician, 79 (8): (2009). L5.4. Karakurt, F., Sahin, I., Güler, S., Demirbas, B., Culha, C., Serter, R., Aral, Y., Bavbek, N., “Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: A randomised controlled study”, Advances in Therapy, 25 (4): 321-328 (2008). 31 L5.5. Al Robaee, A., Al-Zolibani, A., Al-Shobaili, HA., Aslam, M., “Update on hirsutism”, Acta Dermatoven APA, 17 (3): 103-119 (2008). L5.6. Branco, CC., Cancelo, MJ., “Comprehensive clinical management of hirsutism”, Gynecological Endocrinology, 26 (7): 484-493 (2010). L5.7. Maharaj, S., Amod, A., “Polycystic ovary syndrome”, Journal of Endocrinology, Metabolism and Diabetes of South Africa, 14 (2): 86-95 (2009). L5.8. Pizzo, A., Borrielli, I., Raffone, E., Vaiarelli, A., Stella, NC., “The interference of the flutamide on the sexual differentiation of a male fetüs. A case report”, Giornale italiano di ostetricia e ginecologia, 31 (8/9): 363-365 (2009). L5.9. Kriplani, A., Thulkar, J., Agrawal, N., Kulshrestha, V., et al, “A Comparative Study of Diane‐35 plus spironolactone and Diane ‐35 Plus Finasteri de in Cases of Hirsutism and Acne”, Int J Endocrinol Metab, 7 (4): 235-241 (2009). L5.10. Lakshmi, C., “Hormone therapy in acne”, Indian J Dermatol Venereol Leprol, 79 (3): 322-37 (2013). L5.11. Jiang-yuan, L., “Idiopathic hirsutism and its diagnosis and treatment”, Chinese Journal of practical internal medicine, 27 (23): (2007). L5.12. Palacios, A., “Advances in the diagnosis and treatment of hirsutism in adolescent and young adult”, Revista Venezolana de Endocrinología y Metabolismo, 6 (1): 35-38 (2009). L5.13. Blume-Peytavi, U., “How to diagnose and treat medically women with excessive hair”, Dermatologic Clinics, 31 (1): 57-65 (2013). L5.14. Caswell, AH., “Evolutionary Basis of Homosexuality – a Hypothesis of Socio-sexual Interaction”, (2011). L5.15. Czernichow, PRP., “GH treatment of non growth hormone deficient short stature”, Rev. Venez. Endocrinol. Metab, 6 (1): 27-29 (2008). L5.16. Pugeat, M., Kaddar, N., Raverot, V., “Recommended Treatment Modalities for Hyperandrogenism”, Polycystic Ovary Syndrome: Contemporary Endocrinology pp 295-306 (2008). 32 L5.17. Metwally, M., “Hirsutism”, Obstetrics, Gynaecology & Reproductive Medicine, 22 (8): 211–214 (2012). L5.18. Hernandez-Escareno, A., "Comparing The Hormone, Metabolic, And Lipid Profiles Of Reproductive Age Women And The Effects Of Dried Apple Supplementation And Resistance Exercise In Women With Polycystic Ovary Syndrome", Florida State University, Electronic Theses, Treatises and Dissertations. Paper 4086 (2009). L5.19. Lumachi, F., Zulian, E., Scaroni, C., “Cost-effective Therapy in Patients with Idiopathic Hirsutism”, Expert Review of Pharmacoeconomics and Outcomes Research, 4 (3): 297-306 (2004). L5.20. Sahin, Y., Kelestimur, F., “Medical Treatment Regimens of Hirsutism”, Reproductive BioMedicine Online, 8 (5): 538-546 (2004). L5.21. Reismann, P., Liko, I., Patocs, A., “Pharmacological options for treatment of hyperandrogenic disorders”, Mini Reviews in Medicinal Chemistry, 9: (9): 11131126 (2009). L5.22. 2013 Treatment Compendium of of Clinical Hirsutism in Practice Guidelines; Premenopausal http://dx.doi.org/10.1210/CCPG.9781936704668.ch20; Evaluation Women, Published and DOI: Online: November 20, 2013. 33 L6 (A16). Yildirim, Y., M.M. Inal, Sanci, M., Yildirim, YK., Mit, T., Polat, M., Tinar, S., “Development of Uterine Sarcoma after Tamoxifen Treatment for Breast Cancer: Report of Four Cases”, Int J Gynecol Cancer, 15 (6): 1239-1242 (2005). L6.1. Moinfar, F., Azodi, M., Tavassoli, FA., “Uterine sarcomas”, Pathology, 39 (1): 55-71 (2007). L6.2. Huang, GS., Gunter, MJ., Arend, RC., Li, M., Arias-Pulido, H., Prossnitz, ER., Goldberg, GL., Smith, HO., “Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma”, American Journal of Obstetrics & Gynecology, 203 (3): 242.e1 -242.e5 (2010). L6.3. Lavie, O., Barnett-Griness, O., Narod, SA., Rennert, G., “The risk of developing uterine sarcoma after tamoxifen use. International Journal of Gynecological Cancer, 18 (2): 352–356 (2008). L6.4. Teo, SY., Babagbemi, KT., Peters, HE., Mortele, KJ., “Primary Malignant Mixed Müllerian Tumor of the Uterus: Findings on Sonography, CT, and Gadolinium-Enhanced MRI”, American Journal of Roentgenology, 191 (1): 278283 (2008). L6.5. Harry, VN., Narayansingh, GV., Parkin, DE., “Uterine leiomyosarcomas: a review of the diagnostic and therapeutic pitfalls”, The Obstetrician & Gynaecologist, 9 (2): 88–94 (2007). L6.6. Gottwald, L., Gora, E., Korczynski, J., Piekarski, JH., Morawiec, Z., JesionekKupnicka, D., Sowa, P., Cialkowska-Rysz, A., Bienkiewicz, A., “Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor”, Journal of Obstetrics and Gynaecology Research, 34 (4): 721–725 (2008). L6.7. Suprasert, P., Khunamornpong, S., “Carcinosarcoma arising in uterine didelphys after tamoxifen therapy for breast cancer: a case report”, J Med Assoc Thai, 93 (5): 608-12 (2010). L6.8. Buccoliero, AM., Fambrini, M., Gheri, CF., Castiglione, F., Garbini, F., Barbetti, A., et al. “Surveillance for Endometrial Cancer in Women on Tamoxifen: The Role of Liquid-Based Endometrial Cytology – Cytohistological Correlation in a Population of 168 Women”, Gynecol Obstet Invest, 65 (4): 240–246 (2008). 34 L6.9. Saim, M., Cote, JF., Morel, O., Malartic, C., Akerman, G., Gray, F., Barranger, E., “Malignant mixed müllerian tumor of the uterus following tamoxifen for breast cancer: Case report”, Gynécologie Obstétrique & Fertilité, 36 (2): 166– 168 (2008). L6.10. Homer, L., Muller, M., Dupre, PF., Lucas, B., Pradier, O., “Uterine sarcoma associated with tamoxifen use after breast cancer: Review of the pathogenesis”, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 38 (8): 629– 633 (2009). L6.11. Brennan, MF., Antonescu, CR., Maki, RG., “Leiomyosarcoma”, Management of Soft Tissue Sarcoma, p.113-127 (2013). L6.12. Yıldırım, Y., Toz, E., “The Effect of Long-Term Tamoxifen Usage on the Lower Part of Female Genital Tract in Breast Cancer Survivors: A Review”, Marmara Medical Journal, 20 (3): 196-201 (2007). L6.13. Xiaonan, Z., Jingliang, C., Feifei, W., Mengtian YS., “One case: malignant mixed Mullerian tumor of the uterus”, Practical Journal of Radiology, 29 (8): (2013). L6.14. van Meurs, HS., Dieles, JJ., Stel, HV., “A uterine leiomyoma in which a leiomyosarcoma with osteoclast-like giant cells and a metastasis of a ductal breast carcinoma are present”, Annals of Diagnostic Pathology, 16 (1): 67–70 (2012). L6.15. Vasconcelos, ALC., Nunes, B., Duarte, C., Mendonca, V., Ribeiro, J., Jorge, M., Grillo, IM., “Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma—A report of 8 cases and review of the literature”, Reports of Practical Oncology & Radiotherapy, 18 (5): 251–260 (2013). L6.16. Caramelo, O., Marinho, C., Rebelo, T., et al., “A Case of Endometrial Stromal Sarcoma with Synchronous Bilateral Adenocarcinoma of Ovary,” Case Reports in Obstetrics and Gynecology, 2012: 1-5 (2012). L6.17. Koukouliata, A., “Malignant mixed mullerian tumor in two patients receiving tamoxifen therapy”, Prog Health Sci, 1 (1): 167-170 (2011). L6.18. Barry, L., Baxter, G., Pitchamuthu, H., Crooks, JE., Rajan, P., Ahmad, I., “Aggressive bladder leiomyosarcoma in a patient receiving tamoxifen therapy”, Journal of Clinical Urology, 6: 327-329 (2013). 35 L6.19. Shor, AC., "Src kinase inhibitors for the treatment of sarcomas: Cellular and molecular mechanisms of action", Graduate School Theses and Dissertations, University of South Florida (2007). L7 (A27). Onay H., Ugurlu T., Aykut A., Pehlivan S., M. Inal, Tinar S., Ozkinay C., Ozkinay F., “Rapid prenatal diagnosis of common aneuploidies in amniotic fluid using quantitative fluorescent polymerase chain reaction”, Gynecol Obstet Invest, 66 (2): 10410 (2008). L7.1. Cirigliano, V., Voglino, G., Ordoñez, E., Marongiu, A., Paz Cañadas, M., Ejarque, M., Rueda, L., Lloveras, E., Fuster, C., Adinolfi, M., “Rapid prenatal diagnosis of common chromosome aneuploidies by QF-PCR, results of 9 years of clinical experience, Prenat. Diagn, 29 (1): 40–49 (2009). L7.2. Faas, BHW., Cirigliano, V., Bui, TH., “Rapid methods for targeted prenatal diagnosis of common chromosome aneuploidies”, Seminars in Fetal & Neonatal Medicine, 16 (2): 81-87 (2011). L7.3. Yan,C., Yu-ning,Z., Shi-ming,L., Jian-fei,Y., Yu, M., “Establishment and Application of 18-STR Database in Han Population from Zhejiang Province”, J SUN Yat-sen Univ (Med Sci),31 (1):122-128 (2010). L7.4. Langlois, S., Duncan, A., “Use of a DNA method, QF-PCR, in the prenatal diagnosis of fetal aneuploidies”, J Obstet Gynaecol Can, 33 (9): 955-60 (2011). L7.5. Rivkees, SA., Hager, K., Hosono, S., Wise, A., Li, P., Rinder, HM., Gruen, JR., “A Highly Sensitive, High-Throughput Assay for the Detection of Turner Syndrome”, The Journal of Clinical Endocrinology & Metabolism, 96 (3): (2011). L7.6. Yan-Ping, L., Jing C., Shu-Fang, J., Zhang, L., Zhi-Ying, G., et al. “Development of Multiple Quantitative Fluorescent PCR for Rapid Diagnosis of Common Aneuploidy and It's Clinical Application”, Heredity, 11 (32): 1141-1146 (2010). L7.7. Xiangyu, Z., Yali, H., “Advances in diagnosis of fetal chromosomal abnormalities methods”, Chinese Journal of perinatal medicine, 12 (2): (2009). 36 L7.8. Allingham-Hawkins, DJ., Tokunaga, J., Winsor, E., fluorescent polymerase Chitayat, D., Cirigliano, V., Summers, A., Chun, K., “Prospective validation of quantitative chain reaction for rapid detection of common aneuploidies”, Genetics in Medicine, 13 (2): 140–147 (2011). L7.9. Ai-qun, X., Xu-ming, B., Jun-tao, L., Feng-xia, Y., Wei-min, Z., Na, H., Jing, Z., “Establishment of multiple quantitative fluorescent polymerase chain reaction assay and its application in rapid prenatal diagnosis of common chromosome aneuploidies”, Chinese Journal of obstetrics and Gynecology, 45 (7): (2010). L7.10. Atef, SH., Hafez, SS., Mahmoud, NH., Helmy, SM., “Prenatal diagnosis of fetal aneuploidies using QF-PCR: the egyptian study”, J Prenat Med, 5 (4): 83–89 (2011). L7.11. Manlong, Q., Yuanyuan, Z., Harpole, LX., Zhao, Y., “QF-PCR in the diagnosis of chromosomal abnormality in male infertility”, Genetic, 8: (2011). L7.12. Scott, P., Podemski, L., Wyatt, KB., Walker, C., et al. “Toward Optimal Detection of the Common Prenatal Aneuploidies by Quantitative Fluorescent– Polymerase Chain Reaction: Comparison of Two Commercial Assays”, Genetic Testing and Molecular Biomarkers, 16 (8): 943-947 (2012). L7.13. Ozturk, E., Ugur, MG., Cebesoy, FB., Aydın, A., Sever, T., Balat, O., “Good prognosis for primary ovarian pure nongestational choriocarcinoma using the EMA/CO regime”, Eur. J. Gynaec. Oncol, 31 (1): 123-125 (2010). L7.14. Wei, J., Lei, F., “Human short tandem repeat sequence correlation technique and its application in forensic science progress”, Chinese Journal of New Clinical Medicine, 11: (2011). L7.15. Dikensoy, E., Balat, O., Pehlivan, S., Cebesoy, FB, Kutlar, AI., Sever, T., Baltacı, V., “A false negative QF-PCR and Trisomy 18-Trisomy 9 mosaicism”, J Turk Soc Obstet Gynecol, 8 (1): 67- 70 (2011). L7.16. Helmy, SMH., Essawi, M., Bassiouni, R., Gaber, KR., “Rapid PNCD for Common Aneuploidies Uusing QF-PCR in Egyptian Women”, Research Journal of Medicine and Medical Sciences, 4 (2): 446-451 (2009). 37 L7.17. Furtado, LV., Jama, MA, Paxton, CN., Wilson, AA., Gardiner, AE., Lyon, E., Geiersbach, KB., “Aneuploidy Detection in Paraffin Embedded Tissue from Products of Conception by Mini-STR Genotyping”, Fetal & Pediatric Pathology, 32 (2): 133-150 (2013). L7.18. Güngör, ANÇ., Hacıvelioğlu, S., Uludağ, A., Gencer, M., et al “Fetal Anöploidi Açısından Yüksek Riskli Gebeliklerin QF-PCR İle Analizi”, International Journal of Clinical Research, 1 (1): 17-21 (2013). L8 (A8). M.M. Inal, Hanhan, M., Pilanci, B., Tinar, S., “Fallopian Tube Malignancies: Experience of Social Security Agency Aegean Maternity Hospital”, Int J Gynecol Cancer, 14 (4): 595-599, (2004). L8.1. Pectasides, D., Pectasides, E., Economopoulos, T., “Fallopian Tube Carcinoma: A Review”, The Oncologist, 11 (8): 902-912 (2006). L8.2. Goodman, MT., Shvetsov, YB., “Incidence of Ovarian, Peritoneal, and Fallopian Tube Carcinomas in the United States, 1995-2004”, Cancer Epidemiol Biomarkers Prev, 18 (1): 132-139 (2009). L8.3. Bendavid, C., Pasquier, L., Watrin, T., Morcel, K., Lucas, J., et al. “Phenotypic variability of a 4q34 → qter inherited deletion: MRKH syndrome in the daughter, cardiac defect and Fallopian tube cancer in the mother”, European Journal of Medical Genetics, 50 (1): 66–72 (2007). L8.4. Kietpeerakool, C., Suprasert, P., Srisomboon, J., Pantusart, A., “Primary Carcinoma of the Fallopian Tube: A Clinicopathologic Analysis of 27 Patients”, J Med Assoc Thai, 88 (10): 1338-43 (2005). L8.5. Lin, CX., Shanling, WL., Xiao, X., Xuemei, Z., “Primary Fallopian Tube Carcinoma: A Clinical Analysis of 25 Patients”, Practical Journal of Obstetrics and Gynecology, 24 (5): (2008). L8.6. Goswami, PK., Kerr-Wilson, R., McCarthy, K., “Cancer of the fallopian tube”, The Obstetrician & Gynaecologist, 8 (3): 147–152 (2006). L8.7. Yane, Z., Bright, L., River, D., “One Case:Bilateral Calcific Carcinoma of Fallopian Tube”, Practical Journal of Radiology, 24 (8): (2008). 38 L8.8. Stein, RG., Diessner, J., Hönig, A., Wischhusen, J., Dietl, J., “Fallopian tube tumors: an overview”, Atlas of Genetics and Cytogenetics in Oncology and Haematology, 17 (11): 773-787 (2013). L8.9. Ştefănescu, BI., Muscă, S., Ştefănescu, RM., Pricop, M., şi Farmacie, FD. M., “Primitive Fallopian Tube Carcinoma – About 3 Cases. Clinical Study”, ObstetricăGinecologie II, 10 (1): 140-145 (2011). L8.10. Giri, SK., Nayak, B., “Malignancy and Fallopian Tubes: An In-depth Study”, in The Fallopian Tubes, ed., Tripathy, SN., 17: 149-154 (2013). L8.11. Kalampokas, E., Kalampokas, T., Tourountous, I., “Primary fallopian tube carcinoma”, European Journal of Obstetrics & Gynecology and Reproductive Biology, 169 (2): 155–161 (2013). L8.12. Shuzhi, D., Bin, S., “The original tubal adenocarcinoma metastatic carcinomas to spleen: 1 case report and literature review”, Journal of Hebei Medical University, 31 (2): (2010). L8.13. Yuanjing, H., Fengxia, X., “Retroperitoneal lymphadenectomy influence on survival prognosis of primary Carcinoma of fallopian tube”, The Chinese Journal of practical Gynecology and obstetrics, 2010: 443-445 (2010). L8.14. Jianqin, H., Li, W., Zhiling, Z., “Analysis of 22 cases with primary fallopian tube carcinoma diagnosis”, Chinese Journal of Cancer, 21 (8): (2011). L8.15. Aiqin, R., Yu, L., “Fallopian tube carcinoma misdiagnosed as Carcinoma of the vagina: analysis of 1 cases”, Chinese Journal of Misdiagnosis, 24: (2011). L8.16. Yue, L., Chun, H., Liping, Y., Jingjing, L., “Double uterus with endometrium and fallopian tubes of double tumor of 1 cases”, The journal of practical obstetrics and Gynecology, 25 (3): (2009). L8.17. Bharti, MK., Chauhan, A., Sabharwal, R., “Primary Fallopian Tube Adenocarcinoma: A Case Report”, IJPSR, 2 (11): 3002-3005 (2011). 39 L9 (A25). M.M. Inal, Yildirim Y., Ertopcu K., Avci ME., Ozelmas I., Tinar S., “Effect of the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up)”, Eur J Contracept Reprod Health Care, 13 (3): 238-42 (2008). L9.1. Brito, MB., Ferriani, RA., Quintana, SM., Yazlle, MEHD., de Sá, MFS., Vieira, CS., “Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study”, Contraception, 80 (6): 519–526 (2009). L9.2. Li, HWR., Wong, CYG., Yeung, WSB., Ho, PC., Ng, EHY., “Serum antimüllerian hormone level is not altered in women using hormonal contraceptives”, Contraception, 83 (6): 582–585 (2011). L9.3. Dilbaz, B., Ozdegirmenci, O., Caliskan, E., Dilbaz, S., Haberal, A., “Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels”, Contraception, 81 (6): 510–514 (2010). L9.4. Arribas-Mir, L., Rueda-Lozano, D., Agrela-Cardona, M., Cedeño-Benavides, T., Olvera-Porcel, C., Bueno-Cavanillas, A., “Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain”, Contraception, 80 (5): 457–462 (2009). L9.5. Brito, MB., Nobre, F., Vieira, CS., “Hormonal Contraception and Cardiovascular System”, Arq. Bras. Cardiol, 96 (4): 81-89 (2011). L9.6. Oderich, CL., Wender, MCO., Lubianca, JN., Santos, LM., de Mello, GC., “Impact of etonogestrel-releasing implant and copper intrauterine device on carbohydrate metabolism: a comparative study”, Contraception, 85 (2): 173–176 (2012). L9.7. Hohmann, H., “Examining the efficacy, safety, and patient acceptability of the etonogestrel implantable contraceptive”, Patient Prefer Adherence, 3: 205– 211 (2009). L9.8. Guazzelli, CAF., de Queiroz, FT., Barbieri, M., Barreiros, FA., Torloni, MR., Araujo, FF., “Metabolic effects of contraceptive implants in adolescents”, Contraception, 84 (4): 409–412 (2011). 40 L9.9. Zal, F., Mostafavi-Pour, Z., Amini, F., Heidari, A., “Effect of vitamin E and C supplements on lipid peroxidation and GSH-dependent antioxidant enzyme status in the blood of women consuming oral contraceptives”, Contraception, 86 (1): 62–66 (2012). L9.10. Oderich, CL., “Estudo comparativo do Implante Subdérmico de Etonogestrel e do DIU de Cobre no Metabolismo dos Carboidratos”, PhD Thesis, Universidade Federal do Rio Grande do Sul, (2010). L9.11. Jin-jin, L., Xin-yan, L., “The Clinical Etonogestrel Implant”, International journal Performance of of reproductive Single Rod health/family planning, 4: (2013). L9.12. Bruni, V., Seravalli, V., Scarselli, G., “Contraccezione ormonale e rischio cardiovascolare”, SIC Donna news, 5 (2): 4-30 (2012). L9.13. Brito, MB., Ferriani, RA., Quintana, SM., de sá, MFS., Vieira, CS., “Absence of adverse hepatic or renal effects with the etonogestrel-releasing contraceptive implant inserted immediately postpartum”, Open Access Journal of Contraception, 1: 127–133 (2010). L9.14. Milica, B., Milica, M., “Hormonska kontracepcija - prednosti i zablude”, Medicinski Podmladak, 60 (1-2): 133-138 (2009). L9.15. Hedderson, M., “Contraception Before and After GDM”, Gestational Diabetes During and After Pregnancy, 21: 317-329 (2010). L10 (A26). Yildirim Y., Gultekin E., Avci ME., M.M. Inal, Yunus S., Tinar S., “Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer”, Int J Gynecol Cancer, 18 (2): 223-7 (2008). L10.1. Zhang, Y., Shi, J., Li, Y., Wei, L., “Cardiomyocyte death in doxorubicininduced cardiotoxicity”, Archivum Immunologiae et Therapiae Experimentalis, 57 (6): 435-445 (2009). L10.2. Fjällskog, MLH., Janson, ET., Falkmer, UG., Vatn, MH., Öberg, KE., Eriksson, BK., “Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors”, Neuroendocrinology, 88: 53–58 (2008). 41 L10.3. Paoli, EE., Kruse, DE., Seo, JW., Zhang, H., Kheirolomoom, A., et al. “An optical and microPET assessment of thermally-sensitive liposome biodistribution in the Met-1 tumor model: Importance of formulation”, Journal of Controlled Release, 143 (1): 13–22 (2010). L10.4. Duggan, ST., Keating, GM., “Pegylated Liposomal Doxorubicin”, Drugs, 71 (18): 2531-2558 (2011). L10.5. Strother, R., Matei, D., “Pegylated liposomal doxorubicin in ovarian cancer”, Ther Clin Risk Manag, 5: 639–650 (2009). L10.6. Steer, CB., “Chemotherapy for Ovarian Cancer in the Older Adult”, Current Treatment Options in Oncology, 10 (3-4): 159-170 (2009). L10.7. Maradia, K., Guglin, M., “Pharmacologic prevention of anthracyclineinduced cardiomyopathy”, Cardiol Rev, 17 (5): 243-52 (2009). L10.8. Yiwei, Z., Yuanjian, L., “Recent insights into doxorubicin-induced cardiomyocyte death”, International Journal of Clinical and Pathological Science, 2: (2011). L10.9. Henderson, IC., “Development of PEGylated Liposomes, in Drug Delivery in Oncology: From Basic Research to Cancer Therapy (eds F. Kratz, P. Senter and H. Steinhagen)”, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany (2011). L10.10. Ceyhan, C., Turgut, H., "Acute Transient Diastolic Dysfunction Induced By 5-Fluorouracil Treatment: A Case Report”, Journal of Cardiac Research TM, 32: (2005). L10.11. Lyseng-Williamson, KA., Duggan, ST., Keating, GM., “Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies”, BioDrugs, 27 (5): 533-540 (2013). L10.12. Hartung, GA., Mansoori, GA., “In vivo General Trends, Filtration and Toxicity of Nanoparticles”, Journal of Nanomaterials & Molecular Nanotechnology, 2 (3): 1-21 (2013). L10.13. Zhenhua, Z., Jingbo, W., “Cytotoxicity Effect of Thermo-chemotherpy with Pegylated Liposomal Doxorubicin on Human Esophageal Carcinoma in vitro”, Cancer Research on Prevention and Treatment, 38 (7): (2011). 42 L10.14. Zhang, Y., Zhang, Q., Zeng, SX., Hao, Q., Lu, H., “Inauhzin Sensitizes p53-Dependent Cytotoxicity and Tumor Suppression of Chemotherapeutic Agents”, Neoplasia, 15 (5): 523–534 (2013). L10.15. Mansoori, G.A., “In vivo General Trends, Filtration and Toxicity of Nanoparticles”, Journal of Nanomaterials & Molecular, 2013 L11 (A18). M.M. Inal, Incebiyik, A., Sanci, M., Yildirim, Y., Polat, M., Pilanci, B., Nayki, C., Camuzcuoglu, H., “Ovarian Cysts in Tamoxifen-Treated Women with Breast Cancer”, Eur J Obstet Gynecol Reprod Biol, 120 (1): 104-106 (2005). L11.1. Fleming, JS., Beaugié, CR., Haviv, I., Chenevix-Trench, G., Tan, OL., “Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses”, Molecular and Cellular Endocrinology, 247 (1–2): 4– 21 (2006). L11.2. Peano, BJ., Crabtree, JS., Komm, BS., Winneker, RC., Harris, HA., “Effects of Various Selective Estrogen Receptor Modulators with or without Conjugated Estrogens on Mouse Mammary Gland”, Endocrinology, 150 (4): 1897-1903 (2009). L11.3. Harris, HA., Chennathukuzhi, VM., Zhang, X., Mekonnen, B., et al. ”Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats”, The Journal of Steroid Biochemistry and Molecular Biology, 112 (1-3): 40–46 (2008). L11.4. Lin, L., Shu-zhen, W., Zhen-yu, Z., Yan, Z., Hong-chuan, J., Jie, L., “Follow-up of benign gynecologic diseases in patients treated with tamoxifen for breast cancer”, National Medical Journal of China, 25: (2010). L11.5. Baigent, A., Lashen, H., “Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer”, Fertility and Sterility, 95 (7): 2429.e5– 2429.e7 (2011). L11.6. Mofrad, MH., Shandiz, FH., Roodsare, FV., Toktam Moghima, T., “Evaluation of Ovarian Cysts in Breast Cancer Cases on Tamoxifen”, Asian Pacific J Cancer Prev, 11: 161-164 (2010). 43 L11.7. Qin Wu, Q., Xiaozhong, C., Yiyong, W., “Effects of Tamoxifen on uterus and ovary in patients with breast cancer”, Chongqing Medicine Journal, 36 (16): (2007). L11.8. Oliva, P., Roncoroni, C., Radaelli, E., Brunialti, E., Rizzi, N., De Maglie, M., Scanziani, E., et al. “Global Profiling of TSEC Proliferative Potential by the Use of a Reporter Mouse for Proliferation”, Reproductive Sciences, 20 (2): 119-128 (2013). L11.9. Yıldırım, Y., Toz, E., “The Effect of Long-term Tamoxifen Usage on the Lower PArt of Female Genital Tract in Breast Cancer Survivors: A Review”, Marmara Medical Journal, 20 (3): 196-201 (2007). L11.10. Guastalla, J.P., Tredan, O., Ray-Coquard, I., Labidi, I., Bonnin, N., Bachelot, T. L “Hormonothérapie adjuvante (produits, durée) doit-elle être modulée par le profil biologique de la tumeur (niveau d’hormonosensibilité, statut d’HER2 et prolifération)”, Cancer, 2006, pp 385-399 (2006). L11.11. Hsiao, W., Weimin, K., Xiunan, L., Yi, D., “Endocrine therapy for breast cancer and its impact on female genital mutilation”, The Chinese Journal of practical Gynecology and Obstetrics, 1 (3): 817-819 (2008). L11.12. Zhonglin, F., Haiping, L., Cuizhi, G., Yun-Tao, L., “Changes of serum estradiol and follicular stimulating hormone after tamoxifen treatment in breast cancer cases”, Chinese Journal of Clinical Physicians, 1: (2012). L11.13. Matiluko, AF., Crystal, AM., “Adnexal torsion in a postmenopausal woman on tamoxifen”, Trends Urology, Gynecol. Sexual Health, 14 (5): 30–32 (2009). L12 (A17). M.M. Inal, Ertopcu, K., Ozelmas, I., “The Evaluation of 318 Intrauterine Pregnancy Cases with An Intrauterine Device”, Eur J Contracept Reprod Health Care, 10 (4): 266-271 (2005). L12.1. Van Oppenraaij, RHF., Jauniaux, E., “Predicting adverse obstetric outcome after early pregnancy events and complications: a review”, Hum. Reprod. Update, 15 (4): 409-421 (2009). 44 L12.2. Merki-Feld, GS., Schwarz, D., Imthurn, B., Keller, PJ., “Partial and complete expulsion of the Multiload 375 IUD and the levonorgestrel-releasing IUD after correct insertion”, European Journal of Obstetrics & Gynecology and Reproductive Biology, 137 (1): 92–96 (2008). L12.3. Ganer, H., Levy, A., Ohel, I., Sheiner, E., “Pregnancy outcome in women with an intrauterine contraceptive device”, American Journal of Obstetrics and Gynecology, 201 (4): 381.e1–381.e5 (2009). L12.4. Yu, J., Li, J., Li, H., Li, J., Xie, C., Zhu, C., “Comparative study on contraceptive efficacy and clinical performance of the copper/low-density polyethylene nanocomposite IUD and the copper T220C IUD”, Contraception, 78 (4): 319–323 (2008). L12.5. Snell, BJ., “Assessment and Management of Bleeding in the First Trimester of Pregnancy”, Journal of Midwifery & Women’s Health, 54 (6): 483–491 (2009). L12.6. Brahmi, D., Steenland, MW., Renner, RM, Gaffield, ME., Curtis, KM., “Pregnancy outcomes with an IUD in situ: a systematic review”, Contraception, 85 (2): 131–139 (2012). L12.7. Moschos, E., Twickler, DM, ”Intrauterine devices in early pregnancy: findings on ultrasound and clinical outcomes”, American Journal of Obstetrics and Gynecology, 204 (5): 427.e1–427.e6 (2011). L12.8. Gyang, A., Mirando, S., “Gräfenberg ring retained for 15 years: A case report”, The European Journal of Contraception and Reproductive Health Care, 11 (4): 319-321 (2006). L12.9. Owen, C., Sober, S., Schreiber, CA., “Controversies in family planning: desired pregnancy, IUD in situ and no strings visible”, Contraception, 88 (3): 330-3 (2013). L12.10. Mirena IUD Lawsuit Moves, Mirena IUD Helpline Watches. "The Mirena IUD is Manufactured by Bayer..." (2013). L12.11. Veloso, MD., Lobos, AG., Aliste, SN., Rojas, GC., García, MP., Matzler, PP., “Post-insertion ultrasonographic control of intrauterine device”, Rev Chil Obstet Ginecol, 76 (1): 15 – 20 (2011). 45 L12.12. Rowen, T., Creinin, MD., “Highlights (and lowlights) from the past year in contraception: the US unintended pregnancy rate and controversies in providing contraception”, Update: Contraception, 24 (8): 29-35 (2012). L12.13. Dean, G., Goldberg, AB., Zieman, M., Barss, VA., “Overview Of Mirena IUD Complications, Medical Perspective”, Mirena IUD Lawsuit News, (2013). L13. (A3). Taner, C., M. Inal, Basogul, O., Onoglu, A., Karanfil, C., Tinar, S., Ispahi, C., “Comparison of the Clinical Efficacy and Safety of Flutamide versus Flutamide plus an Oral Contraceptive in the Treatment of Hirsutism”, Gynecol Obstet Invest, 54 (2): 105108 (2002). L13.1. Koulouri, O., Conway, GS., “A systematic review of commonly used medical treatments for hirsutism in women”, Clinical Endocrinology, 68 (5): 800– 805 (2008). L13.2. Escobar-Morreale, HF., Carmina, E., Dewailly, D., Gambineri, A., Kelestimur, F., Moghetti, P., et al. “Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society”, Hum. Reprod. Update, 18 (2): 146-170 (2012). L13.3. Castelo-Branco, C., Moyano, D., Gómez, O., Balasch, J., “Long-term safety and tolerability of flutamide for the treatment of hirsutism”, Fertility and Sterility, 91 (4): 1183–1188 (2009). L13.4. Sahin, Y., Kelestimur, F., “Medical treatment regimens of hirsutism”, Reproductive BioMedicine Online, 8 (5): 538–546 (2004). L13.5. Al-Robaee, A., Al-Zolibani, A., Al-Shobaili, HA., Aslam, M., “Update on hirsutism”, Acta Dermatoven APA, 17 (3): 103-119 (2008). L13.6. Paradisi, R., Venturoli, S., “Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period”, Eur J Endocrinol, 163 (1): 139-147 (2010). L13.7. Castelo-Branco, C., Cancelo, MJ., “Comprehensive clinical management of hirsutism”, Gynecological Endocrinology, 26 (7): 484-493 (2010). 46 L13.8. Lis-huang, M., Mei-yu, Y., Xiao-ke, W., “Treatment of adolescent polycystic ovary syndrome”, Foreign medical sciences (maternal and child health division), 16 (3): (2005). L13.9. Lumachi, F., Zulian, E., Scaroni, C., “Cost-effective therapy in patients with idiopathic hirsutism”, Expert Review of Pharmacoeconomics & Outcomes Research, 4 (3): 297-306 (2004). L13.10. Hartmann, KE., Jerome, RN., Lindegren, ML., et al. “Primary Care Management of Abnormal Uterine Bleeding”, Rockville (MD): Agency for Healthcare Research and Quality (US); Comparative Effectiveness Reviews, No. 96 (2013). L13.11. Manieri, DC., Di Bisceglie, C., Brocato, L., “Terapia farmacologica di irsutismo e androgenizzazione”, L’Endocrinologo, 4 (3): 118-130 (2003). L14. (A4). Vardar, E., Maral, I., M. Inal, Ozguder, O., Tasli, F., Postaci, H., “Comparison of Gram Stain and Pap Smear Procedures in the Diagnosis of Bacterial Vaginosis”, Infect Dis Obstet Gynecol, 10 (4): 203-207 (2002). L14.1. Fitzhugh, VA., Heller, DS., “Significance of a diagnosis of microorganisms on pap smear”, J Low Genit Tract Dis, 12 (1): 40-51 (2008). L14.2. Eriksson, K., Forsum, U., Bjornerem, A., Platz-Christensen, JJ., Larsson, PG., ”Validation of the use of Pap-stained vaginal smears for diagnosis of bacterial vaginosis”, APMIS, 115 (7): 809–813 (2007). L14.3. Niño, LR., Manzanero, RZ., Urdaneta, JC., Martínez, VG., Maribel, N., “Bacterial vaginosis: evaluation of diagnostic methods”, Kasmera, 32 (1): 43-51, (2004). L14.4. Eriksson, K., Adolfsson, A., Forsum, U., Larsson, PG., “The prevalence of BV in the population on the Åland Islands during a 15-year period”, APMIS, 118 (11): 903–908 (2010). L14.5. Ngaojaruwong, N., Vuthiwong, C., et al. “Prevalence of Abnormal Papanicolaou Smear in Pregnant Women at Phramongkutklao Hospital”, Thai Journal of Obstetrics and Gynaecology, 16 (3): 179-185 (2008). 47 L14.6. Alves, VAF., Filho, AC., Namiyama, G., Filho, AL., et al. “Liquid-based cytology by DNA-Cytologic system (DCS) – efficacy in identification of vaginal microflora”, DST – J bras Doenças Sex Transm, 16 (4): 27-31 (2004). L14.7. Eriksson, K., “Bacterial Vaginosis: Diagnosis, Prevalence, and Treatment”, Linköping University Electronic Press, Linköping, (2011). L14.8. Karasahin, E., Gungor, S., Ceyhan, ST., Keskin, U., Baser, I., “The association of contraceptive usage with the frequency of the most common etiological agents of vaginal infection”, Balkan Military Medical Review, 11 (1): 34-39 (2008). L15. (A15). Sehirali, S., M.M. Inal, Yildirim, Y., Balim, Z., Kosova, B., Karamizrak, T., Sanci, M., Topcuoglu, N., Tinar, S., “Prothrombin G20210A Mutation in Cases with Recurrent Miscarriage: A Study of the Mediterranean Population”, Arch Gynecol Obstet, 273 (3): 170-173 (2005). L15.1. Toth, B., Vocke, F., Rogenhofer, N., Friese, K., Thaler, CJ., Lohse, P., “Paternal Thrombophilic Gene Mutations Are Not Associated with Recurrent Miscarriage”, American Journal of Reproductive Immunology, 60 (4): 325–332 (2008). L15.2. Zoossmann-Diskin, A., Gazit, E., Peleg, L., Shohat, M., Turner, D., “Thrombophilic polymorphisms in Israel”, Blood Cells, Molecules, and Diseases, 41 (2): 230–233 (2008). L15.3. Glueck, CJ., Pranikoff, J., Khan, N., Riaz, K., et al. “High factor XI, recurrent pregnancy loss, enoxaparin”, Fertility and Sterility, 94 (7): 2828–2831 (2010). L15.4. Zoossmann-Diskin, A., “The origin of Eastern European Jews revealed by autosomal, sex chromosomal and mtDNA polymorphisms”, Biology Direct, 5 (1): 57-75 (2010). L15.5. Zonouzi, AP., Chaparzadeh, N., Ghorbian, S., Sadaghiani, MM., et al. “The association between thrombophilic gene mutations and recurrent pregnancy loss”, Journal of Assisted Reproduction and Genetics, 30 (10): 1353-1359 (2013). 48 L15.6. Gawish, GEH., Al-Khamees, O., “Molecular Characterization of Factor V Leiden G1691A and Prothrombin G20210A Mutations in Saudi Females with Recurrent Pregnancy Loss”, J Blood Disorders Transf, 4 (6): 1-7 (2013). L16. (A12). Yildirim, Y., Tinar, S., Yildirim, YK., M.M. Inal, “Comparison of PituitaryOvarian Function in Patients Who Have Undergone Successful Renal Transplantation and Healthy Women”, Fertil Steril, 83 (5): 1553-1556 (2005). L16.1. Douglas, NC., Shah, M., Sauer, MV., “Fertility and Reproductive Disorders in Female Solid Organ Transplant Recipients”, Seminars in Perinatology, 31 (6): 332-338 (2007). L16.2. Abe, T., Ichimaru, N., Okumi, M., Imamura, R., Isaka, Y., Takahara, S., Kokado, Y. Okuyama, A., “Pregnancy after renal transplantation: A single-center experience”, International Journal of Urology, 15 (7): 587–592 (2008). L16.3. Richman, K., Gohh, R., “Pregnancy after renal transplantation: a review of registry and single-center practices and outcomes”, Nephrol. Dial. Transplant, 27 (9): 3428-3434 (2012). L16.4. Gassen, DT., Herter, LD., Garcia, C., Marroni, R., Maiga Milagre, M., Barros, V., “Hormonal aspects of gynecological patients with transplanted kidney and Nefropathies”, Revista HCPA, 29 (3): (2009). L16.5. Yıldırım, Y., Sönmez, S., Toz, E., İnal, M., Aykas, A., Uslu, A., “Solid organ (kidney, liver, pancreas-kidney, heart, lung and heart-lung) transplantations and pregnancy”, Marmara Medical Journal, 21 (1): 79-88 (2008). L16.6. Kim, JM., Song, RK., Kim, MJ., Lee, DY., Jang, HR., Kwon, CHD., et al. “Hormonal Differences Between Female Kidney Transplant Recipients and Healthy Women With the Same Gynecologic Conditions”, Transplantation Proceedings, 44 (3): 740-743 (2012). L16.7. Pietrzak, B., Wielgos, M., Kaminski, P., Jabiry-Zieniewicz, Z., Bobrowska, K., “Menstrual Cycle and Sex Hormone Profile in Kidney-Transplanted Women”, Neuroendocrinology Letters, 27 (1-2): 198-202 (2006). 49 L17. (A22). M.M. Inal, Yildirim, Y., Ertopcu, K., Ozelmas, I., “The Predictors of Retained Products of Conception Following First-trimester Pregnancy Termination with Manual Vacuum Aspiration”, Eur J Contracept Reprod Health Care, 11 (2): 98-103 (2006). L17.1. Müngen, E., Dundar, O., Babacan, A., “Postabortion Doppler Evaluation of the Uterus; Incidence and Causes of Myometrial Hypervascularity”, JUM, 28 (8): 1053-1060 (2009). L17.2. Kara, F., Dogan, NU., Bati, S, Demir, S., Durduran, Y., Celik, C., “Early surgical abortion: Safe and effective”, The European Journal of Contraception and Reproductive Health Care, 18 (2): 120-126 (2013). L17.3. Russo, JA., DePiñeres, T., Gil, L., “Controversies in family planning: retained products of conception”, Contraception, 86 (5): 438-42 (2012). L17.4. Maged, A., Gaffar, H., Mostafa, W., “Role of transvaginal ultrasound in detection of retained products of conception after abortion”, Saudi J Health Sci, 1 (3): 151-155 (2012). L17.5. Mentula, M., “Second trimester medical termination of pregnancy: procedure, immediate complications and the risk of repeat termination”, University of Helsinki, Faculty of Medicine, Institute of Clinical Medicine, Doctoral Thesis (2012). L18. (A14). Yildirim, Y., M. Inal, Tinar S., “Necrotizing Fasciitis after Abdominal Hysterectomy: A Report on Five Cases”, Arch Gynecol Obstet, 273 (2): 126-128 (2005). L18.1. Bharathan, R., Hanson, M., “Diagnostic laparoscopy complicated by group A streptococcal necrotizing fasciitis”, J Minim Invasive Gynecol, 17 (1): 121-123 (2010). L18.2. Faro, S., Faro, JP., “Necrotizing Soft-tissue Infections in Obstetric and Gynecologic Patients”, Clinical Obstetrics & Gynecology, 55 (4): 875–887 (2012). L18.3. Chifu, C., Diaconu, C., Andriescu, L., Palaghiu, R., Grigoras, O., Damian, N., “Rare complication of colostomy”, Chirurgia, 101 (4): 433-436 (2007). 50 L18.4. Kurdoğlu, Z., Akşin, S., Kolusarı, A., “Abdominal histerektomi sonrası insizyon bölgesinde nekrotizan fasit: olgu sunumu”, Anatol J Clin Investig, 5 (4): 186-188 (2011). L18.5. Campa, MF., Juliana Cano-Mejia, J., Madenjian, R., "A Review of the Pathogenesis of Necrotizing Fasciitis by Group A Streptococci", The Spectra, The Virginia Engineering and Science Research Journal, (2011). L19. (A10). Sehirali, S., M.M. Inal, Ozsezgin, S., Sanci, M., Atli, O., Nayki, C., Yildirim, Y., Tinar S., “A Randomized Prospective Study of Comparison of Reservoir Ports versus Conventional Vascular Access in Advanced-Stage Ovarian Carcinoma Cases Treated with Chemotherapy”, Int J Gynecol Cancer, 15 (2): 228-232 (2005). L19.1. Goossens, GA., Stas, M., Jérôme, M., Moons, P., “Systematic review: malfunction of totally implantable venous access devices in cancer patients,” Supportive Care in Cancer, 19 (7): 883-898 (2011). L19.2. Cahalane, AK., Rassnick, KM., Flanders, JA., “Use of vascular access ports in femoral veins of dogs and cats with cancer”, Journal of the American Veterinary Medical Association, 231 (9): 1354-1360 (2007). L19.3. Camp-Sorrell, D., “Accessing and Deaccessing Ports: Where Is the Evidence?”, Clinical Journal of Oncology Nursing, 13 (5): 587-590 (2009). L19.4. David, L., Béatrice, L., Justine, GD., Véronique, LG., Chantal, D., et al. “Clinical Outcome After a Totally Implantable Venous Access Port-Related Infection in Cancer Patients: A Prospective Study and Review of the Literature”, Medicine, 91 (6): 309–318 (2012). L19.5. Fernández-de-Maya, J., Richart-Martínez, M., “Variability in management of implantable ports in oncology outpatients”, European Journal of Oncology Nursing, 17 (6): 835–840 (2013). 51 L20. (A5). M.M. Inal, Ertopcu, K., Arici, A., Ozelmas, I., “The Effect of Oral versus Vaginal Misoprostol on Cervical Dilatation in First-trimester Abortion: A Double-blind, Randomized Study”, Eur J Contracept Reprod Health Care, 8 (4): 197-202 (2003). L20.1. Hussain, A., Ahsan, F., “The vagina as a route for systemic drug delivery”, Journal of Controlled Release, 103 (2): 301–313 (2005). L20.2. Yan, Z., Kaiyu, T., Lin T., et al. “Effectiveness and Safety of Oral Misoprostol for Cervical Ripening before Artificial Abortion of First-trimester Pregnancy:A Systematic Review”, Journal of practical Obstetrics and Gynecology, 22 (12): (2006). L20.3. Inal, MM., Yildirim, Y., Ertopcu, K., Ozelmas, I., “The predictors of retained products of conception following first-trimester pregnancy termination with manual vacuum aspiration”, The European Journal of Contraception and Reproductive Health Care, 11 (2): 98-103 (2006). L20.4. Krishna, SV., Ashok, V., Chatterjee, A., “A Review on Vaginal Drug Delivery Systems”, IJBPAS, 1 (2): 152-167 (2012). L20.5. Chang-ping, G., Yan, Z., Jing, F., You-ping, L., et al. “Effectiveness and Safety of Vaginal and Sublinguinal Misoprostol for Cervical Ripening before Artificial Abortion of First-Trimester Pregnancy: A Systematic Review”, The Journal of Evidence Based Medicine, 7 (4): (2007). L21. (A11). Ertopcu, K., M.M. Inal, Ozelmas, I., “Demographic Analysis of PostAbortive and Interval-Administered Hormonal Contraceptive Methods”, Eur J Contracept Reprod Health Care, 10 (1): 1-5 (2005). L21.1. Mittal, S., “Contraception after medical abortion”, Contraception, 74 (1): 56–60 (2006). L21.2. Palanivelu, LM., Oswal, A., “Contraceptive practices in women with repeat termination of pregnancies”, Journal of Obstetrics & Gynaecology, 27 (8): 832834 (2007). L21.3. Prata, N., Bell, S., Holston, M., Gerdts, C., Melkamu, Y., “Factors Associated with Choice of Post-Abortion Contraception in Addis Ababa, Ethiopia”, African Journal of Reproductive Health, 15 (3): (2011). 52 L22.(A7). Yildirim, Y., M.M. Inal, Sanci, M., Sentas, A., Hanhan, M., “Uterine Sarcomas: A 10 Year Experience and A Review of the Literature”, Women’s Oncology Review, 4 (1): 7-12 (2004). L22.1. Gottwald, L., Gora, E., Korczynski, J., Piekarski, JH., Morawiec, Z., et al. “Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor”, Journal of Obstetrics and Gynaecology Research, 34 (4): 721–725 (2008). L22.2. Gómez, ASM., Blanco, RG., Loza, RA., Martínez, AS., Lara, HJMM., Zuani, JGZ., “Uterine Sarcoma: Case Report”, Ginecol Obstet Mex, 80 (3): 224-227 (2012). L22.3. Ertas, IE., Doğan, A., Özdemir, A., Solmaz, U., et al. “The effect of adjuvant treatment modalities on survival outcomes in cytoreductive surgery performed patients with advanced stage uterine sarcomas”, Ege Journal of Medicine, 52 (4): 179-184 (2013). L23. (A6). Tinar, S., Sehirali, S., M.M. Inal, Yildirim, Y., Celik, E., Yigit, S., “Adenosarcoma of the Uterus: A Case Report”, MedGenMed (electronic resource): Medscape General Medicine, 6 (1): 51 (2004). L23.1. Rita Sakr, R., Marzouk, P., Bricou, A., Fabien Demaria, F., Annie Cortez, A., Benifla, JL., “Uterine adenosarcoma associated to lymphovascular emboli: a case report”, Cases Journal, 2 (7515): 1-3 (2009). M. Ulusal kitap yazarlığı veya Ulusal kitaplarda bölüm yazarlığı: M1. Avcı, ME., M.M. İnal., “Gebelik ve Travma”, Temel Kadın Hastalıkları ve Doğum Bilgisi, ed. Ayhan, A., Durukan, T., Günalp, S., et al, Güneş Tıp Kitabevleri; 2. Basım, s353-362 (2008). M2. Avcı ME., M.M. İnal., “Sıvı-Elektrolit Dengesi”, Temel Kadın Hastalıkları ve Doğum Bilgisi, ed. Ayhan, A., Durukan, T., Günalp, S., et al, Güneş Tıp Kitabevleri; 2. Basım, s769-777 (2008). 53 M3. Avcı ME., M.M. İnal., “Premenstrüel Sendrom”, Temel Kadın Hastalıkları ve Doğum Bilgisi, ed. Ayhan, A., Durukan, T., Günalp, S., et al, Güneş Tıp Kitabevleri; 2. Basım, s851-863 (2008). N. Ulusal Bilimsel Toplantılara Katılım: N1. Menapoz ve Hormon Replasman Tedavisi 4. Uludağ Sempozyumu, 4-7 Mart 1999, Bursa. N2. 1. Ulusal Aile Planlaması Kongresi, 14-17 Nisan 1999, Ankara. N3. 7. Ulusal Perinatoloji Kongresi, 2- 6 Mayıs 1999, Antalya. N4. 1st Reproductive Medicine 2000, June 7-10, 2000, Istanbul. N5. 1st International Congress on the Menopause and the 4th National Congress, 17-21 Mayıs 2000, Antalya. N6. 21st century Reproductive Medicine and Endoscopic Surgery Congress, 14-17 September 2000, Kuşadası, Aydın. N7. Türk-Alman Jinekoloji Derneği 4. Kongresi, 30 Mayıs- 3 Haziran 2001, Antalya. N8. 8. Ulusal Jinekolojik Onkoloji Kongresi, 1-5 Mayıs 2002, Antalya. N9. 1. Ege Jinekolojik Endoskopik Cerrahi Sempozyumu, 13-14 Aralık 2002, İzmir. N10. 3. Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi, 20-23 Nisan 2003, Ankara. N11. Güncel İnfertilite ve Yardımcı Üreme Teknikleri Sempozyumu, 24-27 Nisan 2003, İzmir. N12. 5. Türk-Alman Jinekoloji Derneği ve 2.Reproductive Medicine Tartışmalı Konular ve Çözümler Ortak Kongresi, 16-20 Mayıs 2003, Antalya. N13. 4. Ulusal Jinekoloji ve Obstetrik Kongresi, 20-25 Nisan 2004, Antalya. N14. 9. Ulusal Jinekolojik Onkoloji Kongresi, 4-8 Mayıs 2004, Antalya. N15. 2. Ege Jinekolojik Endoskopi Sempozyumu ve Workshop, 10-12 Mart 2005, İzmir. 54 N16. 4. Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi, 20-23 Nisan 2005, Ankara. N17. 10. Ulusal Jinekolojik Onkoloji Kongresi, 19-23 Nisan 2006, Antalya. N18. 5. Ulusal Jinekoloji ve Obstetrik Kongresi, 16-21 Mayıs 2006, Antalya. N19. Doppler USG ve Obstetri’de Uygulamaları Sempozyumu, 1 Aralık 2006, İzmir. N20. 6. Ulusal Jinekoloji ve Obstetri Kongresi, 14-19 Mayıs 2008, Antalya. N21. 10. Ulusal Jinekoloji ve Obstetri Kongresi, 09-13 Mayıs 2012, Antalya. N22. 5. Ulusal Üreme Endokrinolojisi ve İnfertilite Kongresi, 27-30 Eylül 2012, İzmir. N23. 13. Ulusal Jinekolojik Onkoloji Kongresi, 07-11 Kasım 2012, Antalya. O. Eğitim kursu katılımları: O1. Endokrin Hastalıklarda Laboratuar Değerlendirme Kursu, 30 Nisan – 2 Mayıs 2001, İzmir. O2. Neonatal Resüsitasyon Kursu, 25-27 Nisan 2001, İzmir. O3. Fetal Anomaly Scanning Course (ISUOG Outreach Programme), 3 May 1999, Antalya. 55